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Abstract 
 
Mu-opioid receptor (MOR) agonists are effective agents for pain management, but are 
also limited by a number of undesirable effects. One approach to enhance the therapeutic effects 
and minimize the undesirable effects of MOR agonists may be to combine MOR agonists with 
an adjunct targeting a different receptor system. This targeted medical approach, known as 
“combination therapy”, aims to augment the desired effects of the MOR agonist (i.e. 
antinociception) and/or diminish the undesirable deleterious side effects of the MOR agonist. 
This dissertation investigated the utility of this approach in an assay of thermal nociception and 
schedule-controlled responding in male rhesus monkeys with three aims. One aim determined 
the utility of N-methyl D-aspartate (NMDA) receptor antagonists to selectively enhance MOR 
agonist antinociception. A second identified the pharmacological determinants of antinociceptive 
interactions between a nociceptin opioid peptide (NOP) receptor agonist and MOR agonists. A 
third aim investigated the potential for fixed-proportion mixtures of a competitive MOR 
antagonist and MOR agonist to manipulate antinociceptive efficacy. Experimental results did not 
support the utility of NMDA antagonists as adjuncts to selectively enhance MOR agonist 
antinociception. Furthermore, the antinociceptive interactions between a NOP agonist and MOR 
agonists were modest and occurred under a narrow range of conditions. Finally, fixed proportion 
MOR antagonist-agonist mixtures were effective in manipulating antinociceptive in vivo 
efficacy. In conclusion, this dissertation does not provide strong empirical evidence that a 
combination therapy approach will result in clinically effective and selective enhancement of 
MOR agonist analgesia. The dissertation concludes with proposed strategies and novel 
preclinical methods to enhance preclinical-to-clinical translation of effective candidate 
analgesics. 
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Chapter 1: Introduction 
 
Pain as a Problem 
Pain is defined as “an unpleasant sensory and emotional experience associated with 
actual or potential tissue damage or described in terms of such damage” (IASP, 2017). Pain, and 
the management thereof, remains a significant healthcare challenge in the United States and 
worldwide. The estimated financial burden on society associated with patients suffering from 
some aspect of pain is over 550 billion dollars annually (Gaskin and Richard, 2012). Moreover, 
nearly one-third of Americans reported at least one pain symptom within the past three months, 
and nearly one-fifth of American adults are afflicted with chronic pain (Nahin et al, 2015; 
Dahlhamer et al, 2018). Chronic pain is defined as pain persisting for greater than one month, 
and it is often comorbid with various other disorders, ranging from arthritis to cancer (IASP, 
2017). Additionally, pain symptoms are a common reason to visit a medical professional in 
developed countries (Schappert et al, 2006). Furthermore, between 2006 and 2016, more than 
215 million opioid-based prescriptions were written each year (CDC, 2018). Unfortunately, this 
high rate of opioid prescriptions has contributed to the current opioid crisis in the United States 
(Delgado et al, 2018). Taken together, the financial, societal, and individual burdens emanating 
from pain and its treatment highlight the need for preclinical research to develop novel 
analgesics and/or strategies to enhance the therapeutic effects and minimize the undesirable 
effects of opioids for pain management.  
Brief History on Opioid Agonists as Analgesics 
Opioid agonists are one of the longest used psychoactive substances known to man, save 
for alcohol and marijuana. However, throughout much of human history, opioid use was limited 
to the opium poppy (Papaver somniferum), and until relatively recently, the plethora of opioid 
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compounds currently available to modern medicine remained undiscovered. While some 
archaeological discoveries of Papaver date back over 8000 years, the earliest evidence of 
cultivation and use can be traced back to Sumer in 3400 BCE based on the discovery of stone 
tablets referring to the opium poppy as “Huy Gil”, which is roughly translated to “Joy Plant” 
(Brownstein, 1993). This example is merely the earliest widely accepted finding, as nearly every 
major society after Sumer has some evidence of opium utilization either for recreational or 
medicinal purposes (Brownstein, 1993; Presley and Lindsley, 2018). 
While nearly a millennium would pass before a scientific understanding of the nature by 
which opium produces its abuse-related and medicinal effects would arise, opium was readily 
utilized during antiquity. Knowledge of the medicinal properties of the opium poppy quickly 
disseminated from Sumer to the Assyrians to the Egyptians to the Grecians, etc. During these 
times, opium use was most commonly associated with ritualistic and religious rites, as evidenced 
by various fables of its bestowment upon man by various gods and their close association with 
poppies in numerous visual representations (Schiff Jr, 2002). However, there was some evidence 
of opium use for medicinal purposes, namely for euthanasia, when opium would be mixed into a 
cocktail with poison hemlock (Conium maculatum) (Brownstein, 1993).  
The Islamic societies of the early Middle Ages were some of the first to begin 
rudimentary investigations into cataloging the physiological effects of opium in medical texts 
and initiated the introduction of opium to the Far East via the Silk Road (Brownstein, 1993; 
Presley and Lindsley, 2018). Moreover, the famous physician and author of Cannon of Medicine, 
Avicenna, was the first to catalog many of opium’s physiological effects including: analgesia, 
antitussive, gastrointestinal distress, respiratory depression, neuromuscular disturbances, 
hypnosis, and somnolence. However, perhaps more impressive and innovative for the time, was 
 
7 
Avicenna’s recommendations for delivery and dosages of opium. This marked some of the first 
instances of opium standardization for medicinal use (Heydari et al, 2013). This text and its 
subsequent translation to Latin was a key factor in introducing opium to Western medicine, 
where its medicinal potential and use blossomed during the Renaissance (Smith, 1980). 
Since their initial cultivation and through the modern day, the alkaloids of interest that 
are present in opium poppy have been extracted in a similar manner. When the plant is ready to 
be harvested, the bulb is scored with a blade, and a milky wax, usually referred to as opium latex, 
pours from the bulb. Once the latex has dried, it is dissolved in boiling water to remove any 
impurities. When enough liquid has been boiled off, a waxy residue is left, called smoking opium 
(Presley and Lindsley, 2018). Although Papaver somniferum contains various alkaloids, there 
are six that are generally thought to contribute to the prototypical physiological and 
psychological effects of opioids. These six alkaloids are morphine, codeine, thebaine, narceine, 
noscapine, and papaverine.  
Scientific Advancements to Improve Therapeutic Effects and Minimize Undesirable Effects 
Following the initial isolation of morphine from opium poppy by Sertürner in 1804, there 
was a steady increase in the isolation of naturally occurring opioid alkaloids and synthesis of 
synthetic opioid compounds (Courtwright, 2009). For example, codeine was first isolated in 
1832 by Robiquet. Felix Hoffman synthesized the first synthetic opioid, heroin, in 1897 (Science 
History Institute, 2019). Throughout the 20th century, a number of new synthetic opioid 
compounds were generated including: oxycodone, methadone, meperidine, fentanyl, nalbuphine, 
and buprenorphine (Cowan et al, 1977; Sneader, 2005). Buprenorphine’s synthesis also marked 
one of the first attempts to intentionally improve opioid analgesics. The rationale was to create a 
low efficacy opioid agonist that would still produce pain relief while having an improved safety 
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profile (i.e. reduced incidence of respiratory depression). The drug design approach for 
buprenorphine lead to another experimental approach of reducing undesirable opioid side effects 
and increasing antinociceptive potency or efficacy by combining an opioid with an adjunct 
compound active at another receptor system (O’Connell et al, 2014; Li, 2019; Viscus, 2019).  
The concepts of potency and efficacy are important pharmacological factors in the 
context of opioid pharmacology. Potency is “a measure of drug activity expressed in the terms of 
the amount required to produce an effect of given intensity”, whereas efficacy is the maximal 
response produced by a drug (Neubig et al, 2003; Holford and Sheiner, 1981). For example, in 
the context of opioids, buprenorphine is highly potent drug as its antinociceptive effects are 
apparent at relatively low doses; however, buprenorphine is a low efficacy drug as it can only 
produce antinociception (i.e. the action of blocking the detection of a noxious stimulus) against 
relatively low noxious stimulus intensities (Walker, Zernig, and Woods, 1995). In contrast, 
methadone is not a potent drug, but is a high efficacy drug, as it will produce antinociception 
against relatively high noxious stimulus intensities (Mello and Mendelson, 1985; Cornelissen et 
al, 2019). Further, potency and efficacy are not always negatively correlated as the previous 
examples may suggest. For example, fentanyl is a very potent, highly efficacious opioid (Finch 
and DeKornfeld, 1967; France et al, 1992). Potency and efficacy are important defining factors 
in the overall behavioral effects of opioid drugs and have the potential to be manipulated in an 
attempt to improve the clinical utility of these compounds. 
Drug adjuncts are secondary compounds administered in conjunction with another 
primary drug in a targeted medical approach known as “combination therapy”. This practice has 
been successfully implemented for the treatment of a variety of disorders ranging from 
neurological to cardiovascular etiologies (Li, 2019). Moreover, adjuncts are a particularly 
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attractive drug development method because it allows for the potential repurposing of currently 
FDA-approved medications to facilitate the drug development and clinical trial processes (Li, 
2019). This approach is also employed in the pain field (e.g. Vicodin), and could potentially 
serve as one method to enhance or retain the therapeutic effects while also minimizing the 
undesirable effects of opioids (Collins et al, 2018).  In the context of these experiments, an 
adjunct, which could increase opioid antinociceptive potency, would result in less opioid agonist 
being administered to produce similar antinociceptive effects, whereas increasing opioid 
antinociceptive efficacy would be expressed as the opioid and adjunct combination producing a 
greater antinociceptive maximal effect compared to the opioid alone (Li, 2019). 
 The notion of combining an opioid with another compound(s) acting at a different 
receptor target is not a recent development in medicine. For example, opium was commonly 
combined with poison hemlock for the purposes of euthanasia in antiquity; further, spongia 
somnifera, a sponge soaked with a cocktail of: opium, mandrake, poison hemlock, and henbane 
(Hyoscyamus niger), was utilized as an early anesthetic in Europe during the Middle Ages 
(Brownstein, 1993; Prioreschi, 2003). Laudanum (from the Latin meaning, “worthy of praise”) is 
perhaps the earliest example of an opioid combination medication in direct efforts to treat pain 
(Potter, 1902). While laudanum’s initial creation is credited to the Swiss physician Paracelsus, it 
is disputed as to whether or not his original “recipe” indeed included opium (Sigerist, 1941). 
Nevertheless, laudanum first gained notoriety as an analgesic following the English physician 
Thomas Sydenham’s Medical Observations Concerning the History and Cure of Acute Diseases 
publication where he described the opium and ethanol tincture’s exact measurements for the 
mixture (Davenport-Hines, 2004). Therefore, laudanum probably represents the first example of 
an opioid combination medication for pain management. 
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Regardless of whether or not the ethanol “adjunct” of laudanum augmented opium’s 
analgesic effects, Brompton cocktail was the first opioid combination developed with that 
explicit goal. Brompton cocktail was comprised of: an opioid agonist (morphine or heroin), 
cocaine, high-percentage alcohol, chloroform, and syrup (to increase palatability) (Richardson 
and Baker, 1956). The Brompton cocktail was used in both post-operative and palliative care 
regularly during the 1920s (Clark, 2014). Moreover, the elixir was reported to be a superior 
analgesic compared to morphine alone in palliative care units (Melzack, Mount, & Gordon, 
1979). Although Brompton cocktail did succeed in augmenting opioid agonist-induced analgesia, 
more recent investigations suggest this was a non-selective enhancement. For example, some 
heroin/cocaine dose mixtures have been shown to engender greater drug-taking behaviors than 
heroin alone in preclinical drug self-administration procedures (Mello et al, 1995; Negus, 2005). 
As attempts to identify additional opioid combination medications progressed, so did the 
aspiration for their ability to selectively enhance analgesia and even potentially mitigate 
undesirable opioid effects (Smith, 2008; Li, 2019). 
The most typically prescribed opioid combination medications utilize oxycodone or 
hydrocodone as the mu-opioid receptor (MOR) agonist and a non-steroidal anti-inflammatory 
drug (NSAID), such as ibuprofen, or acetaminophen (e.g. Percodan(R), Percocet(R), 
Vicoprofen(R), Vicodin(R)) (Raffa et al, 2010; Li, 2019). Although there is limited clinical or 
preclinical evidence of any additive or synergistic interactions between these two classes when 
co-administered, one hypothesis is that NSAID-induced cyclo-oxygenase-2 (COX-2) inhibition 
or acetaminophen augments the opioid-mediated analgesic effect (Raffa et al, 2010). 
Unfortunately, NSAIDs and acetaminophen have their own undesirable effects such as 
gastrointestinal bleeding, cardiovascular complications, and hepatotoxicity (Sostres et al, 2010). 
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Thus, there is a need for preclinical research to develop and evaluate candidate opioid adjuncts 
that enhance the therapeutic effects and minimize the undesirable effects in the context of pain 
management.  
 There are at least four potential approaches for the opioid+adjunct to produce an “opioid-
sparing effect” (which is defined as a “reduction in the opioid dose administered without a loss in 
analgesic efficacy” (Nielsen et al, 2017)): (1) Prolong analgesia duration, (2) enhancement of 
analgesic efficacy, (3) enhancement of analgesic potency, (4) minimization or elimination of 
undesirable opioid-related effects (Smith, 2008; Li, 2019; Viscusi et al, 2019). Currently, 
NSAIDs and acetaminophen are the only opioid adjuncts available in an FDA-approved 
prescription medication. Thus, knowledge regarding the usefulness of this approach to improve 
opioid analgesics is relatively limited. Accordingly, the aim of this dissertation was to examine 
candidate opioid agonist adjuncts to selectively modulate opioid antinociception in preclinical 
assays of nociception.  
Basic Opioid Pharmacology and Modulation of Nociception 
MOR agonists are a class of molecules that bind to and activate the MOR receptor. The 
MOR receptor is one of the three “classical” opioid receptors, the other two being the delta-
opioid receptor (DOR) and the kappa-opioid receptor (KOR) (Stein, 2016). The different 
classifications of these receptors are based on their peptide structure and the preferential binding 
of the three main endogenous opioids to them. For example, endorphins preferentially bind to 
MORs, enkephalins to DORs, and dynorphins to KORs; however, these neuropeptides are not 
selective and there is some overlap in binding profiles across the three opioid receptors (Stein, 
2016). There also exists a fourth subtype of opioid receptor, the nociceptin-opioid peptide (NOP) 
receptor; however, the NOP receptor is not considered a “classical” opioid receptor due to 
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significant differences in the peptide composition of the receptor and NOP receptor insensitivity 
to the opioid antagonist naltrexone (Stein, 2016; Toll et al, 2016).  
All three classical opioid receptors and the NOP receptor are G-protein coupled receptors 
(GPCR) which, when activated, initiate a cascade of intracellular signaling events altering 
cellular function (Bohn et al, 1999; Stein, 2016). All opioid receptors are coupled to a specific G-
protein categorized as a Gi/o and are composed of three subunits: alpha, beta, and gamma. The 
alpha subunit is a GTPase, which hydrolyzes the molecule guanosine triphosphate (GTP) to 
release energy contained in the phosphodiester bond at the gamma phosphate of the GTP 
molecule. The latter two subunits form a beta-gamma complex (Goldstein et al, 1971; Manglik et 
al, 2012; Wu et al, 2012; Thompson et al, 2012). Ligand binding to the opioid receptor initiates 
an intracellular signaling cascade following a conformational change of the receptor. This allows 
dissociation of the alpha subunit and beta-gamma complex from the receptor. Once this occurs, 
the alpha subunit inhibits production of the secondary messenger cyclic adenosine 
monophosphate (cAMP) and the beta-gamma complex activates multiple G protein-coupled 
inwardly-rectifying potassium (GIRK) channels and inhibits calcium channels (Ingram and 
Williams, 1994; Tedford and Zamponi, 2006; Luscher and Slesinger, 2010). The beta-gamma 
complex also inhibits sodium channels, hyperpolarization-activated cyclic nucleotide-gated 
(HCN) channels, transient receptor potential vanilloid (TRPV1) channels, and acid-sensing ion 
channels (ASICs) in dorsal root ganglion (DRG) neurons. Furthermore, the beta-gamma complex 
can also modulate pre- and post-synaptic cellular excitability by inhibition of glutamate-
mediated excitatory post-synaptic potentials (EPSPs) (Herz et al, 1989; Endres-Becker et al, 
2007; Spahn et al, 2013; Cai et al, 2014). The net result of these intracellular events is an 
increase in membrane potential and decreased likelihood of an action potential (Stein, 2016).  
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Although mu, delta, kappa, and NOP receptors share similar signaling mechanisms, 
differences in receptor density and neuroanatomic locations result in differential pharmacological 
effects. For example, MOR agonists produce euphoria and respiratory depression, which are two 
of the major undesirable effects of clinically available opioid analgesics (Hamilton and Cullen, 
1953; Levitt et al, 1977; Montandon and Slutsky, 2019). DOR agonists can produce convulsions, 
KOR agonists can produce dysphoria (Tortella et al, 1983; Wadenberg, 2003), and NOP agonists 
may impair learning and memory (Toll et al, 2016). Similar to the opioid receptors’ overlap in 
function, there is also a generous overlap in the distribution of these receptors across the nervous 
system. As the focus of this dissertation is on modulating nociception, the most pertinent location 
of opioid receptors (and specifically MORs) is along the spinothalamic tract. 
The anterolateral pain processing system is the most prominent nociceptive pathway 
responsible for transmitting noxious stimuli information from the periphery to the brain (Kandel 
et al, 2013). This pathway projects from primary nociceptors along primary afferents -neurons 
that transmit information to the central nervous system (CNS) - that synapse in the outer laminae 
of the dorsal horn of the spinal cord, which in turn project to the thalamus and then relays the 
nociceptive signal to a number of different cortical regions (Kandel, 2013). The anterolateral 
pain processing system includes myelinated Aδ fibers and unmyelinated C fibers, both of which 
carry the nociceptive signal from the periphery to the CNS. Aδ fibers and C fibers each encode 
different types of sensory stimulation from the periphery, and each are innervated by both high- 
and low- threshold mechanoreceptors. The major difference between the two is the speed at 
which they will conduct an action potential. Aδ fibers tend to transmit more rapidly, while C 
fibers more slowly, and this discrepancy is due to the differences in myelination (Aδ fibers are 
myelinated, and C fibers are not) (Traub and Mendell, 1988). Furthermore, the anterolateral pain 
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processing system is also comprised of descending efferent neurons (i.e. neurons that transmit 
information away from the CNS). Descending neurons project from the parabrachial nucleus and 
rostroventral medulla to the soma (i.e. neuronal cell body) of nociceptive afferents in the dorsal 
horn of the spinal cord and are responsible for modulating nociceptive signals being transmitted 
from the periphery (Kandel, 2013). Some opioid receptors have been shown to have similar 
effects on transmission of such nociceptive signals. Mu, kappa, and delta receptor activation 
have all been shown to inhibit nociceptive signaling along the anterolateral pain processing 
system at the level of the periphery (Ko et al, 1999, 2000; Butelman et al, 2004). However, the 
effect of NOP receptor activation is less certain. Existing data contradictorily suggest that the 
endogenous ligand nociceptin/orphanin FQ (N/OFQ) can both produce antinociception (Ko et al, 
2002) and block MOR-, DOR-, and KOR-mediated antinociception (Chen et al, 2007). It is 
through modulation of nociceptive signaling by opioids and/or novel compounds along this 
pathway that many preclinical assays assess the utility of candidate analgesics. 
Preclinical Assessment of Candidate Analgesics 
The preclinical investigation of candidate analgesics or opioid adjuncts involves three 
major components. The first component is research subject selection. Nonhuman primates 
(NHPs) are the most phylogenetically similar preclinical research subjects to humans, and their 
utilization should enhance vertical translation from preclinical to clinical results. Furthermore, 
the distribution and density of opioid receptor subtypes is much more similar between NHPs and 
humans than rodents and humans (Weerts, 2007). For example, rodents have a higher ratio of 
delta:mu receptors than do humans or nonhuman primates. Beyond this, several potential MOR 
adjuncts have been previously shown to have differential effects in rodents than in NHPs (Weerts 
et al, 2007). In addition, one of the independent variables manipulated in this dissertation is 
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MOR agonist efficacy, and differences in MOR agonist efficacy have been reported such that 
NHPs are more representative of MOR agonist antinociceptive efficacy in humans than rodents 
(Walker et al, 1993, 1995; Maguire and France, 2014; Cornelissen et al, 2018b). 
The second component is the noxious stimulus and there are numerous types of 
experimental noxious stimuli. This dissertation utilized a thermal noxious stimulus, specifically 
warmed water. In a warm-water tail withdrawal procedure, a subject’s (e.g. rhesus monkey) tail 
is immersed in a container of warmed water hypothesized to be noxious (50 or 54 °C) and the 
latency for the animal to remove its tail is measured (Dykstra and Woods, 1986). Candidate 
analgesics or adjuncts can then be administered to determine if administration leads to an 
increased tail withdrawal latency indicative of an antinociceptive effect. For example, the MOR 
agonist morphine produces dose-dependent antinociception (Dykstra and Woods, 1986). These 
results and more recently published results suggest that this procedure is sensitive to clinically 
used opioid analgesics (Walker et al, 1993; Gatch et al, 1998; Negus et al, 2009; Banks et al, 
2010a,b; Maguire and France, 2014; Cornelissen et al, 2018a,b; Cornelissen 2019). However, the 
warm-water tail withdrawal procedure is known to have poor behavioral selectivity and thus is 
susceptible to false positives due to motor suppression or incoordination (Whiteside et al, 2013; 
Negus, 2019).  
To facilitate interpretation of results in the warm-water tail withdrawal procedure, a 
second behavioral procedure was utilized in this dissertation to provide one metric of behavioral 
selectivity. Schedule-controlled responding has been used since the early 1960’s to determine 
pharmacological properties of drugs related to potency, time course, and receptor mechanisms 
(Cook and Kelleher, 1962; Kelleher and Morse, 1964). Initially, the procedure was developed to 
determine if some drug effects were more sensitive to positively reinforced behaviors as opposed 
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to negatively reinforced behaviors (i.e. shock-avoidance tasks) (Cook and Kelleher, 1962). The 
procedure utilizes animal subjects that have been trained to respond on a manipulandum at a 
predetermined (typically) ratio or interval for the presentation of a food reinforcer. Once 
behavior is stable, drugs can then be administered to the animal to investigate drug or dose 
related effects on operant rates of responding. The rate-decreasing effects of opioids in NHPs 
have been well characterized, and there is strong concordance between studies regarding the 
potency rankings for opioids to produce decreases in rates of responding (Negus et al, 1993; 
Butelman et al, 1996; Negus et al, 2003, Stevenson et al, 2003, 2005; Banks et al 2010a,b; 
Cornelissen et al, 2018a,b, 2019). Moreover, there is a strong consensus that efficacy is an 
important determinant in this procedure with low efficacy opioids producing limited rate 
suppression and high efficacy opioids producing greater to even full rate suppression (Cook and 
Kelleher, 1962; Byrd, 1975; Howell et al, 1988; Negus et al, 1993; Negus et al, 2003; Stevenson 
et al, 2005; Banks et al, 2010; Cornelissen, et al, 2018a,b; Cornelissen et al 2019). Thus, this 
dissertation utilized these two experimental assays (warm-water tail withdrawal and schedule-
controlled responding) to address the following three specific aims: 
 
1.) Determining the utility of the NMDA receptor antagonists ketamine and MK-
801 as candidate adjuncts to MOR agonists in the selective production of anti-
allodynia using dose-addition analysis in male rhesus monkeys. 
 
One receptor system that might be a biological target of interest for potential adjuncts to 
MOR agonists in combination medication therapy is the glutamate system. The N-methyl D-
aspartate (NMDA) receptor is a cation-selective ion channel found throughout the central 
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nervous system (CNS), which is preferentially permissible to sodium, potassium, and calcium 
(Vyklicky et al, 2014). The endogenous ligand is the glutamate neurotransmitter, and functional 
receptors are tetramers comprised of two GluN1 subunits in combination with two additional 
subunits: two GluN2s, two GluN3s, or one of each (Monyer et al, 1992; Ulbrich & Isacoff, 
2008). Current NMDA receptor channel gating models suggest that ligand binding induces a 
conformational change promoting the closure of the ligand-binding domain and opening of the 
cation channel. Interestingly, the molecular binding requirements for NMDA receptor activation 
are dictated by the presence of specific subunits. To this end, GluN2 containing tetramers require 
binding of 2 glutamate molecules and 2 glycine co-agonist molecules (Watkins & Evans, 1981; 
Johnson & Ascher, 1987). GluN3 containing tetramers are activated solely upon glycine binding 
and are much more sparsely expressed in the CNS (Pérez-Otaño et al, 2016). Beyond this, a 
magnesium ion is bound in the ion channel pore when the NMDA receptor is inactive, must be 
displaced to allow intracellular cation flux (Furukawa et al, 2005). 
Three lines of evidence support the evaluation of NMDA receptor antagonists as MOR 
agonist adjuncts. First, glutamate is not merely the primary excitatory neurotransmitter in the 
CNS, but also serves a critical role in the transmission of nociceptive impulses from the 
periphery to cortical regions through the spinal cord via the spinothalamic tract (Westlund et al, 
1992; Meldrum, 2000). Anatomical studies have demonstrated the presence of NMDA receptors 
at both the spinal level within the dorsal horn and supraspinal level in nociceptive pathways 
(Rodriguez-Munoz et al, 2012; Bourbia et al, 2014). More specifically, immunolocalization 
experiments in NHPs (Macaca fascicularis) have indicated that nearly half of spinothalamic 
tract-contacting cells contained glutamatergic terminals (Westlund et al, 1992). Given the role of 
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glutamate in nociceptive transmission along the spinothalamic tract, we hypothesized that that 
inhibition of glutamate transmission should dampen nociceptive transmission. 
Second, a number of NMDA receptor antagonists produce antinociception in multiple 
preclinical models of pain across a number of different animal species. In mice, it has been 
demonstrated that: (1) memantine and ketamine are antinociceptive in an assay of acetic acid-
induced writhing (Malec et al, 2008) and (2) MK-801 and ACEA-1011 prevent the development 
of formalin-induced nociception (Vaccarino et al, 1993). Furthermore, in rats, NMDA receptor 
antagonists have shown antinociceptive effects at both the cellular and organismal level. 
Administration of the compound 7-chlorokynurenate (7CK) reduced activity (i.e. action potential 
firing rates) of dorsal horn C-fibers (Dickenson and Aydar, 1991) and this finding was expanded 
upon with ketamine and MK-801-induced antinociception in an assay of lactic acid-induced 
stretching (Hillhouse and Negus, 2016). Finally, the antinociceptive effects of ketamine, MK-
801, phencyclidine (PCP), and dextrorphan have been demonstrated in rhesus macaques using an 
assay of thermal nociception (France et al, 1989). These findings have been interpreted to 
suggest that NMDA antagonists such as ketamine might have analgesic properties and serve as 
candidate MOR agonist adjuncts.  
Lastly, several preclinical studies have supported the utility of NMDA receptor 
antagonists as adjuncts to MOR agonists across several pain states and model organisms. For 
example, ketamine was shown to potentiate the acute antinociceptive effects of the MOR 
agonists morphine, fentanyl, and sufentanil in mice, but not the antinociceptive effects of the 
DOR agonist SNC80 or the KOR agonist U50,488H (Baker et al, 2002). Furthermore, in rats, the 
active ketamine metabolites S(+)- and R(-)-norketamine enhanced morphine-induced 
antinociception in models of: thermal nociception, peripheral neuropathy, and inflammation 
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(Holtman Jr et al, 2008). Finally, MK-801, (-)-6-phosphonomethyl-decahydroisoquinoline-3-
carboxylic acid (LY235959), and (+)-(1-hydroxy-3-aminopyrrolidine-2-one) ((+)-HA-966) all 
increased the electric shock intensity tolerated by squirrel monkeys (Saimiri sciureus) compared 
to morphine alone (Allen and Dykstra, 2001). Overall, these preclinical studies are supported by 
clinical evidence suggesting that although ketamine has undesirable effects, it also may serve as 
a useful adjunct to mu agonists (for review and recent meta-analysis, see Lee and Lee, 2016). 
This dissertation evaluated NMDA antagonist and MOR agonist interactions using a 
preclinical capsaicin-induced thermal allodynia procedure. Allodynia is defined as the expression 
of a pain-related pain elicited by a stimulus that is normally innocuous and can be apparent in 
various clinical conditions including post-operative pain, cancer, and arthritis (Ko et al, 1998; 
IASP, 2017). Preclinically, allodynia can be evoked via transdermal capsaicin application (Ko et 
al, 1998). Capsaicin is a pungent vanilloid irritant found in chili peppers of the genus Capsicum 
and is responsible for producing their “spicy” flavor. Capsaicin binds to and activates the 
transient receptor potential cation channel subfamily V member 1 (TRPV1) receptor (Caterina et 
al, 1997). As a non-selective cation channel, TRPV1 activation increases membrane potential 
(Caterina et al, 1997). Transdermal capsaicin application will elicit a transient burning sensation 
in both humans and NHPs and results in allodynia by lowering nociceptive thresholds; thus, 
capsaicin application may model inflammatory clinical pain states (Simone et al, 1987, 1989; Ko 
et al, 1998). Ketamine has been proposed to possess anti-inflammatory properties (De Kock et 
al., 2013; Wang et al., 2013). Moreover, results from our own laboratory have challenged the 
claim that either ketamine or MOR/ketamine combinations produce antinociception against acute 
noxious stimuli, and opioid/NMDA antagonist interactions have not been previously assessed in 
preclinical allodynia models (Banks et al, 2010a). Finally, capsaicin stimulates glutamate release 
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from sensory afferents, and is sensitive to blockade via activation of peripheral MORs (Winter et 
al, 1995; Ko et al, 1998). Taken together, this background strongly supports the investigation of 
opioid/NMDA combinations in models of allodynia that are responsive to peripheral opioid 
activation. Thus, antinociceptive interactions were assessed using an assay of capsaicin-induced 
thermal allodynia. We hypothesized that NMDA antagonists would selectively enhance mu 
agonist-induced antinociception vs. mu agonist-induced rate suppression.  
 
2.) Identifying potential pharmacological determinants of the antinociceptive 
interaction between the NOP receptor agonist adjunct, Ro 64-6198, and MOR 
agonists in male rhesus monkeys. 
 
Another potential receptor system that might function as a useful mu opioid agonist 
adjunct is the nociceptin opioid peptide (NOP) system. The NOP receptor is a Gi/o-coupled 
GPCR and considered to be the “non-classical” fourth opioid receptor (Toll et al, 2016). The 
NOP receptor is activated by the endogenous opioid peptide known as nociceptin/orphanin FQ 
(N/OFQ) and, unlike the 3 “classical” opioid receptors, is relatively insensitive to antagonism by 
naltrexone (Toll et al, 2016). Moreover, a paucity of commonly employed exogenous opioid 
ligands are active at the NOP receptor and produce agonist-like effects except for buprenorphine, 
and this activity is typically only apparent at very high doses (Khroyan et al, 2009). [(1S,3aS)-8- 
(2,3,3a,4,5, 6-hexahydro-1H-phenalen-1-yl)-1-phenyl-1,3,8-triaza- spiro[4.5]decan-4-one (Ro 
64-6198) is a highly selective and efficacious experimental small molecule NOP receptor agonist 
that has contributed to our improved understanding of NOP receptor functions (Jenck et al, 2000; 
Dautzenberg et al, 2000). While Ro 64-6198 was initially synthesized as a potential treatment for 
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Alzheimer’s, depression, or stress disorders, targeting these indications with NOP receptor 
agonists have not been successful (Jenck et al, 2000; Dautzenberg et al, 2001). Moreover, the 
receptors are expressed in cortical brain regions and throughout the spinal cord implicating a 
potential role in antinociception, anxiety, and reinforcement (Toll et al, 2016). Two lines of 
evidence support potential interactions between mu-opioid and NOP receptors. 
First, NOP receptors are colocalized with mu-opioid receptors in both spinal and brain 
regions involved in nociceptive signaling pathways (for review, see Toll et al., 2016). For 
example, both the NOP and MOR receptor are expressed in ascending and descending pathways 
of the spinothalamic tract and in nociceptive processing/modulatory regions such as 
somatosensory cortex, thalamus, parabrachial nucleus, rostral ventral medulla, spinal cord, and 
within the DRG (Neal et al, 1999; Florin et al, 2000; Toll et al, 2016). More specifically, NOP 
receptors in the dorsal horn are mainly distributed through the deep laminae I-III, which is 
important for antinociception (Toll et al, 2016). Thus, due to NOP receptor localization, 
activation of NOP receptors would be hypothesized to produce antinociception. 
Second, preclinical studies have reported species difference in the antinociceptive effects 
of both NOP activation by the endogenous ligand and the selective high-efficacy NOP agonist 
Ro 64-6198 (Jenck et al, 2000; Ko et al, 2008). Intrathecal administration of N/OFQ produced 
antinociceptive effects in nonhuman primates, but biphasic effects on antinociception in mice 
(Ko et al, 2009). Moreover, systemic Ro 64-6198 produced antinociception in rhesus monkeys 
(Ko et al, 2009), but not rodents (Reiss et al, 2008). Further highlighting potential species 
differences, systemic combinations of Ro 64-6198 and a mu-opioid agonist produced additive 
antinociceptive effects in mice (Reiss et al, 2008), but synergistic antinociceptive effects in 
rhesus monkeys (Cremeans et al, 2012).  
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Overall, this literature supports further evaluation of NOP and mu-opioid agonist 
interactions. Previous studies examining mu-opioid agonist antinociceptive interactions with 
other receptor systems suggest that one important determinant of these interactions may be MOR 
agonist efficacy (Banks et al, 2010b; Maguire and France, 2014; Negus et al, 2009). However, 
the degree to which mu-opioid agonist efficacy is a determinant of NOP agonist interactions is 
unknown. Therefore, the aim of the present study was to determine the role of mu-opioid ligand 
efficacy in antinociceptive interactions with the NOP agonist Ro 64-6198 in rhesus monkeys 
using previously described procedures (Banks et al, 2010a,b; Stevenson et al, 2003). 
Antinociceptive interactions between Ro 64- 6198 and six mu-opioid ligands (17-
cyclopropylmethyl- 3,14β-dihyroxy-4,5α-epoxy-6α-[(3 ́ -isoquinolyl)acetamindo]morphinan 
(NAQ), buprenorphine, nalbuphine, morphine, oxycodone, and methadone) that vary in agonist-
stimulated GTPγS binding from lowest to highest (Selley et al, 1998; Thompson et al, 2004; 
Zaidi et al, 2013) and in their in vivo effectiveness to produce antinociception (Cornelissen et al, 
2018b) were investigated. For comparison, Ro 64-6198 interactions were also investigated with 
the selective high efficacy KOR agonist nalfurafine. Nalfurafine is not a clinically-approved 
analgesic and fails to produce antinociception under conditions that dissociate antinociception 
from behavioral sedation (Endoh et al, 2001; Lazenka et al, 2018). Drug interactions were also 
examined in an assay of schedule-controlled responding in a different cohort of monkeys to 
assess behavioral selectivity to produce antinociception vs. rate suppression. If NOP agonists are 
to be considered as candidate MOR agonist adjuncts, then we would hypothesize that Ro 64-
6198 would robustly and selectively enhance the antinociceptive vs. rate suppressant effects of 
mu-opioid agonists. 
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3.) Expansion of the Furchgott equation for receptor theory by investigating the 
potential for fixed-proportion mixtures of competitive MOR antagonist and 
MOR agonist to manipulate antinociceptive efficacy in male rhesus monkeys. 
 
The Furchgott equation was developed to generate theoretical curves of receptor 
activation level across a range of agonist doses (Ruffolo, 1982). The equation considers both 
agonist and antagonist values including dose, efficacy, affinity, transduction function, and 
receptor number to generate an “estimate” of drug effects. The Furchgott equation applies to 
both in vivo and in vitro procedures measuring varying levels of receptor activation. The present 
aim expanded the Furchgott equation to predict the in vivo effects of a fixed-proportion agonist-
antagonist mixture. 
Fixed-proportion mixtures have been used in both preclinical experimental models and in 
clinically used medications. For example, the application of dose-addition analysis to determine 
the relationship (e.g. subadditive, additive, supra-additive) between two drugs relies upon the 
generation of fixed-proportion mixtures to adequately probe a wide enough range of drug 
combinations to best identify an effect. Moreover, several opioid combination medications 
employ a fixed-proportion mixture (either with an opioid antagonist or other drug). For example, 
the medications suboxone(R) (buprenorphine/naloxone) and Targin(R) (oxycodone/naloxone) 
use a fixed-proportion approach in their dosing (Simpson et al, 2008; Yokell et al, 2011). 
Furthermore, Targin(R) utilizes an opioid antagonist to mitigate the undesirable MOR agonist 
effect constipation. This example represents one potential advantage of a fixed-proportion 
agonist-antagonist approach.  
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Pharmacodynamics is concerned with the affinity and efficacy of drugs at their receptor 
targets. Drug affinity can be precisely measured with ligand binding techniques, but drug 
efficacy to activate receptor signaling and produce downstream effects is a relative measure 
dependent in part on the signaling pathway(s) and downstream effects under consideration, and 
drug efficacies are typically described in relation to some standard high-efficacy ligand (Ruffolo, 
1982; Kenakin, 2012). Although efficacy is challenging to measure, it is clearly relevant in drug 
development. For example, mu-opioid receptor (MOR) ligands differ in their efficacy to activate 
MOR-coupled signal transduction processes and produce MOR-mediated effects such as 
analgesia and respiratory depression. Fentanyl has high MOR efficacy and increasing fentanyl 
doses can produce both antinociception and lethal respiratory depression (Gerak et al., 1994; 
Banks et al., 2010a; Ding et al., 2016). At the other extreme of the efficacy continuum, 
naltrexone has little or no MOR efficacy, produces no agonist effects, and functions as a 
competitive reversible antagonist (Walker et al., 1994; Ko et al., 1998; Bowen et al., 2002). 
Between these extremes are intermediate-efficacy MOR ligands such as nalbuphine and 
buprenorphine, which produce submaximal stimulation of MOR signaling and a subset of 
agonist effects that includes analgesia but only weak respiratory depression (Gerak et al., 1994; 
Pitts et al., 1998; Kishioka et al., 2000). Experiments to investigate the expression and 
consequences of ligand efficacy at MORs or other receptor targets can be useful both to (1) 
determine the efficacy required to produce different effects of interest, and (2) evaluate relative 
efficacy of new ligands as they are developed.  
One common approach to efficacy evaluations relies on the use of irreversible antagonists 
to evaluate the impact of reducing receptor number on expression of drug effects (Furchgott, 
1966; Kenakin, 1993; Bergman et al., 2000). Efficacy requirements for different effects can be 
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estimated, because an irreversible antagonist will produce greater antagonism of effects with 
high- versus low-efficacy requirements (Zernig et al., 1997). Relative efficacies of different 
drugs can be estimated, because an irreversible antagonist will produce greater antagonism of a 
low- versus high-efficacy agonist (Zimmerman et al., 1987; Walker et al., 1998). However, 
studies with irreversible antagonists can be logistically challenging (e.g., due to the long duration 
of antagonist effects), and irreversible antagonists are not available for many receptors of 
interest. Decreases in receptor number can also be accomplished with genetic mutations, as in 
heterozygous and homozygous receptor knockout animals (Grim et al., 2016), but the degree of 
control over the magnitude of that decrease is limited. Receptor theory suggests an alternative, 
more precise, and more flexible strategy to investigate efficacy using mixtures of competitive 
agonists and antagonists. Figure 1 (left panel) shows a theoretical dose-effect function for a high-
efficacy agonist administered alone or in the presence of increasing fixed doses of an antagonist. 
The familiar result is an antagonist dose-dependent rightward shift in the agonist dose-effect 
curve (Ko et al., 1998; Negus et al., 2003). Figure 1 (right panel) shows theoretical effects using 
a different experimental design, in which the agonist is administered in combination with fixed-
proportional doses of the antagonist, such that increasing agonist doses are administered in 
combination with increasing antagonist doses. In this design, the antagonist is expected to 
produce proportion-dependent downward shifts in the agonist dose-effect curve, and mixtures 
with decreasing agonist-to-antagonist proportions have decreasing apparent efficacies to activate 
the receptor. This approach has two potential advantages relative to existing strategies. First, 
agonist-to-antagonist proportion can be precisely manipulated to yield precise increments in 
efficacy. Second, this approach could be applied to any receptor system for which a competitive 
agonist and antagonist are available. 
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Figure 1. Theoretical curves simulated from the Furchgott equation for receptor theory (Ruffolo, 1982). Left panel shows 
rightward shifts in a competitive reversible agonist dose-effect function after pretreatment with increasing fixed doses of 
a competitive reversible antagonist. Right panel shows downward shifts in a competitive reversible agonist dose-effect 
function when agonist and antagonist are co-administered in fixed-proportion mixtures. Equations and definitions of 
terms are shown below the panels. For this simulation, agonist dose A and antagonist dose B vary in KD (i.e., at a dose of 
1, dose = KD); RT was set arbitrarily at 100, and all other variables were set arbitrarily at 1. Note that in the left panel, 
antagonist dose is a fixed proportion p of the agonist dose A, such that B = pA and increased in agonist dose are 
accompanied by increases in antagonist dose. 
 
The goal of Aim 3 was to test the utility of this approach using the MOR agonist fentanyl 
and competitive antagonist naltrexone (Negus et al., 1993; Emmerson et al., 1994, 1996; Walker 
et al., 1994). Effects of these drugs administered alone and in fixed-proportion mixtures were 
determined in an assay of thermal nociception using two thermal stimulus intensities (50 and 
54°C warm water) and compared with effects produced by six other MOR ligands shown 
previously to vary in their relative MOR efficacies in in vitro assays of agonist-stimulated 
GTPγS binding (Emmerson et al., 1996; Selley et al., 1998; Alt et al., 2001; Thompson et al., 
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2004; Yuan et al., 2015). We predicted that the effects of fentanyl, naltrexone, and the mixtures 
would match the predicted results in Fig. 1 (right panel). Additionally, we predicted that the 
maximal effects of fentanyl, naltrexone, and the mixtures could be used to generate efficacy-
effect scales for quantification of both (1) MOR efficacy requirements for antinociception at 50 
and 54°C, and (2) relative efficacies of the six MOR test ligands. 
 
 The overarching goal of this dissertation was to utilize the opioid combination medication 
experimental approach in a nonhuman primate model of thermal nociception to evaluate two 
putative MOR agonist adjuncts. Two experimental design features were common throughout 
these studies. First, fixed-proportion mixtures were utilized when possible to model the clinical 
application of opioid adjunct combination products. Second, behavioral selectivity was assessed 
using an assay of schedule-controlled responding to enhance experimental rigor and provide 
evidence that opioid plus adjunct mixtures were not due to behavioral sedation or impairment. 
Our working hypothesis is that putative MOR agonist adjuncts should selectively enhance the 
therapeutic effects of MOR agonist compared to undesirable MOR agonist effects. Finally, the 
application of fixed-proportion opioid mixtures to principles of receptor theory was examined as 
a method to quantitatively stratify MOR agonists based on in vivo efficacy.   
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Chapter 2: Determining the utility of the NMDA receptor antagonists ketamine and MK-801 as 
candidate adjuncts to MOR agonists in the selective production of anti-allodynia using dose-
addition analysis in male rhesus monkeys. 
 
INTRODUCTION 
 Pain states pose a major public health challenge in the United States and around the 
world; one recent estimate suggest that over one-third of Americans reported pain symptoms 
within the past three months (Nahin, 2015). Mu-opioid agonists, such as hydrocodone and 
oxycodone, are increasingly being prescribed for pain management and from 2000 to 2010 there 
was a 4-fold increase in opioid prescriptions (Comer et al., 2013). However, mu-opioid agonists 
are limited in their clinical utility due to undesirable effects such as sedation and abuse liability. 
One drug development approach may be to combine mu agonists with adjuncts targeting other 
receptor systems to enhance the therapeutic effects (e.g. antinociception) and/or attenuate 
undesirable effects (e.g. sedation) (Dietis et al., 2009).  
 One receptor system that might be a biological target of interest is the glutamatergic 
system. Three lines of evidence support the evaluation of N-Methyl-D-Aspartate (NMDA) 
receptor antagonists as adjunctions to mu-opioid agonists. First, anatomical studies have 
demonstrated the presence of NMDA receptors at both the spinal level within the dorsal horn and 
supraspinal level in nociceptive pathways (Rodriguez-Munoz et al., 2012; Bourbia et al., 2014). 
Second, NMDA receptor antagonists, such as ketamine and dizocilpine (MK-801), produce 
antinociception in some, but not all, preclinical models of pain utilizing mice (Malec et al., 
2008), rats (Hillhouse and Negus, 2016), and monkeys (France et al., 1989; Allen and Dykstra, 
2001; Banks et al., 2010a) as research subjects. Lastly, preclinical studies in rodents have 
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suggested these NMDA receptor antagonists may also enhance the antiallodynic and 
antihyperalgesic effects mu agonists in rodents depending upon the noxious stimulus (Holtman Jr 
et al., 2008; Pascual et al., 2010). Furthermore, these preclinical studies are supported by some 
clinical evidence suggesting that although ketamine has undesirable effects, it also may serve as 
a useful adjunct to mu agonists under certain clinical conditions (for review and recent meta-
analysis, see (McGuinness et al., 2011; Lee and Lee, 2016)). Overall, both preclinical and 
clinical studies support the further consideration of NMDA antagonists as adjuncts to mu 
agonists. 
 The goal of the present study was to determine whether mu-opioid agonist efficacy was a 
determinant of opioid/NMDA interactions in male rhesus macaques using previously described 
procedures for opioid interaction assessment (Stevenson et al., 2003; Banks et al., 2010a). 
Antiallodynic interactions were assessed using an assay of capsaicin-induced thermal allodynia 
for two main reasons. First, ketamine may have anti-inflammatory properties (De Kock et al., 
2013; Wang et al., 2013), attenuates capsaicin-induced allodynia in humans (Park et al., 1995) 
and monkeys (Butelman et al., 2003), and we have previously shown that ketamine alone does 
not produce antinociception in monkeys using a warm water tail-withdrawal procedure (Banks et 
al., 2010a). Thus, one potential reason for the lack of a synergistic interaction between ketamine 
and fentanyl in our previous monkey study (Banks et al., 2010a) could be the preclinical 
nociception procedure. For example, delta-opioid agonist and mu agonist antinociceptive 
interactions were found to be synergistic using a strict thermal noxious stimulus (i.e. warm water 
tail-withdrawal), but additive under thermal allodynia (i.e. capsaicin-induced thermal allodynia) 
conditions (Stevenson et al., 2003; Banks et al., 2010a; Negus et al., 2012). Second, 
opioid/NMDA antagonist interactions have not been previously assessed in preclinical allodynia 
 
30 
models using nonhuman primates as research subjects and under experimental conditions using 
fixed-proportion mixtures and dose-addition analysis. Drug interactions were also evaluated in 
an assay of schedule-controlled responding for the following two reasons. First, nalbuphine, 
oxycodone, ketamine, and MK-801 alone produced dose-dependent effects in this procedure, and 
data from this procedure could be used to quantify the relative potencies of fixed-proportions in 
drug mixtures if one of the drugs (e.g. MK-801) was inactive in the assay of capsaicin-induced 
thermal allodynia. Second, drug or drug mixture effects on schedule-controlled responding 
provide one dependent measure of behavioral depression that may confound measures of 
antiallodynia in pain-stimulated behaviors (i.e. tail withdrawal). Therefore, potency comparisons 
of drug or drug mixture effects in assays of allodynia and schedule-controlled responding may 
provide an experimental index of therapeutic effect selectivity. Based on the preclinical 
literature, we hypothesized that NMDA antagonists would selectively enhance mu agonist-
induced antiallodynia vs. mu agonist-induced rate suppression.  
 
METHODS 
Subjects: 
A total of 7 adult male rhesus macaques (Macaca mulatta) of either Indian or Chinese 
origin and weighing between 10-14 kg served as subjects. Three monkeys were used in studies of 
schedule-controlled responding, and 4 monkeys were used in studies of capsaicin-induced 
thermal allodynia. All animals had prior experimental histories consisting of opioids, cocaine, 
and NMDA antagonist exposure. The diet consisted of laboratory monkey chow (#5049, Purina, 
Framingham, MA), and was supplemented daily with fresh fruits and/or nuts. Monkeys were 
individually housed with free access to water under a 12-h light/12-h dark cycle (lights on from 
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6:00 AM until 6:00 PM). The facility was licensed by the United States Department of 
Agriculture and accredited by AAALAC International. Both research and enrichment protocols 
were approved by the Institutional Animal Care and Use Committee and in accordance with the 
8th edition of the Guide for the Care and Use of Laboratory Animals (Council, 2011). 
Environmental enrichment included: music, movies, puzzle feeders, and chew toys. Furthermore, 
monkeys were afforded opportunities to interact socially using olfactory and auditory cues; 
mirrors provided visual interaction. 
 
Behavioral Procedures  
Assay of Capsaicin-Induced Thermal Allodynia 
 Monkeys were seated in acrylic restraint chairs as described previously (Banks et al., 
2010b). The monkey’s tail was shaved at least once a week 10-12 cm from the tip upward, and 
baseline tail-withdrawal latencies were measured from water heated to 38, 42, 46, and 50 °C. 
The maximal latency was 20 s, and if the monkey had not withdrawn its tail within 20 s, the 
experimenter removed the tail, and a latency of 20 s was assigned. Using this procedure, 
temperature-effect functions were determined in each monkey at the beginning of the behavioral 
session, and the highest temperature that failed to elicit a tail withdrawal was determined (i.e., 
the highest temperature to produce a tail-withdrawal latency of 20 s). Water heated to this 
temperature then served as the thermal stimulus for subsequent allodynia studies during that 
session. Allodynia was elicited by topical capsaicin application (0.3 mL of either 1.22M (n=2) or 
2.44M (n=2) capsaicin) as described previously (Butelman et al., 2004; Banks et al., 2010b). 
After baseline tail-withdrawal latency determinations, the subject’s tail was wiped with an 
alcohol pad and a topical capsaicin patch was prepared as described below (see Drugs); the patch 
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was applied to a region ~ 5 cm from the bottom of the tail for 5 min. After 5 min, the patch was 
removed and tail-withdrawal latencies were redetermined using the thermal stimulus identified 
from the baseline temperature-effect function. Initially, nalbuphine (0.032-0.32 mg/kg), 
oxycodone (0.01-0.32 mg/kg), ketamine (0.32-1.8 mg/kg), and MK-801 (0.0032-0.056 mg/kg) 
were tested alone and each dose was tested once. A single drug or drug mixture dose was 
administered 5 min before topical capsaicin administration and the time course of drug or drug 
mixture effects on tail-withdrawal latencies was determined over the course of 60 min in 15-min 
intervals starting 30 min post-drug or drug mixture administration. Subsequently three mixtures 
(1:0.33, 1:1, and 1:3 mu agonist/NMDA antagonist) of nalbuphine or oxycodone in combination 
with ketamine or oxycodone in combination with MK-801 were examined such that the 
intermediate proportion was 1:1 mu agonist/NMDA antagonist, and 3-fold lower and higher 
proportions were also determined. The fixed proportions for nalbuphine/ketamine and 
oxycodone/ketamine were based on the relative potencies of these compounds in the assay of 
capsaicin-induced thermal allodynia because all compounds were behaviorally active. However, 
fixed proportions of oxycodone/MK-801 were based on the relative potencies of these 
compounds in the assay of schedule-controlled responding because MK-801 did not produce > 
50% maximum possible effect (MPE) in all monkeys up to doses that produced undesirable 
effects. Testing occurred twice weekly on Tuesdays and Fridays. 
 
Assay of Schedule-Controlled Responding 
 Experiments were conducted in each monkey’s housing chamber which also served as the 
experimental chamber as previously described (Banks et al., 2010a). A custom-fabricated 
operant response panel and a food pellet dispenser (Med Associates, ENV-203-1000, St. Albans, 
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VT) were attached to the front of the housing chamber. Panels were operated under a MED-PC 
interface and programmed with an IBM computer using MEDSTATE Notation (MED 
Associates). All behavioral training sessions were comprised of five 30-min cycles for a total 
session duration of 150 min. Two components were incorporated into each cycle. The first 
component was a 25-min time-out period during which responding was recorded, but had no 
scheduled consequences. The second component was a 5-min response period during which the 
right key was illuminated red, and subjects could respond under a fixed-ratio 30 (FR30) schedule 
of food pellet presentation. The response component terminated immediately and lights were 
extinguished if a subject earned the maximum of 10 pellets prior to completion of the 5-min 
period. All monkeys were trained until rates of responding were ≥ 1.0 response/s during all 5 
cycles for 7 consecutive days (data not shown).  
 Behavioral sessions were conducted 5 days per week. Test sessions were usually 
conducted on Tuesdays and Fridays, and training sessions were conducted on Mondays, 
Wednesdays, and Thursdays. Subjects were eligible for participation in test sessions if rates of 
operant responding were ≥ 1.0 response/s on training days that preceded test days. On test days, 
test compounds were administered intramuscular (IM) using a cumulative dosing procedure, in 
which doses of the test drug or drug mixture were administered at the beginning of the 25-min 
time-out period, and each dose increased the total cumulative dose by one-fourth or one-half log 
units in 30-min intervals.  
Initially, dose-effect functions were determined for nalbuphine (0.032-1.8 mg/kg), 
oxycodone (0.01- 1.0 mg/kg), ketamine (0.1-3.2 mg/kg) or MK-801 (0.0032-0.032 mg/kg) alone, 
and each drug was tested twice. Subsequently, three mixtures of ketamine in combination with 
nalbuphine or oxycodone were examined. In addition, three mixtures of MK-801 and oxycodone 
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were also examined. All drug mixtures were studied across a range of three fixed-proportions 
(1:0.33, 1:1, and 1:3 mu agonist/NMDA antagonist) such that the intermediate proportion was 
1:1 mu agonist/NMDA antagonist, and 3-fold lower and higher proportions were also 
determined. Each mixture was tested once, and mixtures were evaluated twice a week. All drugs 
and drug mixtures were tested up to doses that decreased responding >50% of the preceding 
training day’s response rate.  
In addition, drug interactions can also be influence by their relative time courses. The 
relative time courses of ED80 nalbuphine, oxycodone, ketamine, and MK-801 doses were 
compared in the assay of schedule-controlled responding. Either saline, or a single nalbuphine 
(1.65 mg/kg), oxycodone (0.37 mg/kg), ketamine (1.41 mg/kg), or MK-801 (0.039 mg/kg) dose 
was administered, and 5 min response periods were initiated 10, 30, 100, and 300 min after drug 
administration.  
  
Data Analysis 
 For the assay of capsaicin-induced thermal allodynia, raw tail-withdrawal latencies were 
converted to a percent maximum possible effect (%MPE). %MPE was defined as {(Test latency 
– Control latency) ÷ (20 – Control latency)*100} where “test latency” was the average latency 
over the 60-min test session and “control latency” was the average latency over a 60-min control 
session during which vehicle was administered. For the assay of schedule-controlled responding, 
raw rates of operant responding from each test cycle were converted to a percent control rate 
using the average response rate from all 5 cycles from the previous training day in that monkey.  
The effective dose (ED50) that produced 50%MPE or 50% decrease in control rate of 
responding was determined for each mu agonist alone and in combination with either ketamine 
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or MK-801 in each monkey for both assays. ED50 values were determined by interpolation when 
only two data points were available (one below and one above the 50% effect) or by linear 
regression when at least 3 data points were available on the linear portion of the dose-effect 
function. Individual ED50 values were subsequently averaged to yield mean ED50 values and 
95% confidence limits. In addition, potency ratios were calculated for each individual subject by 
dividing the control ED50 value by the test ED50 value. These potency ratios were then averaged 
to yield group mean potency ratios and 95% confidence limits. Potency ratios were considered 
statistically significant if the 95% confidence limits of the group mean potency ratio did not 
include 1.   
To evaluate drug interactions within an assay, both graphical and statistical approaches to 
dose-addition analysis were utilized as described previously (Stevenson et al., 2003; Banks et al., 
2010a). Graphically, data for each drug and drug mixture were plotted as isobolograms at the 
50% effect level. An isobologram plotted one drug dose ± SEM in a mixture as a function of the 
other drug dose ± SEM in a mixture at the overall mixture dose that produced 50% effect. 
Statistical evaluation of drug interactions was accomplished by comparing the experimentally 
determined ED50 value for each mixture (Zmix) with the predicted additivity ED50 value (Zadd) 
as previously described (Tallarida, 2000; Tallarida, 2016). Zadd values were calculated for each 
individual monkey using the equation: 𝑍𝑎𝑑𝑑 = 𝑓𝐴 + 1− 𝑓 𝐵, where Α was the mu agonist 
alone ED50 value, Β was the NMDA antagonist alone ED50 value, and ƒ was a fractional 
multiplier of Α in the computation of the additive total dose. The experiments described in this 
study tested mixtures that yielded values of ƒ=0.25,  ƒ=0.5, and ƒ=0.75, were ƒ is related to the 
proportion of the mu agonist in a mixture per the equation ρA=ƒ/Zadd. When mixtures were 
studied in the assay of capsaicin-induced thermal allodynia, where MK-801 was inactive, the 
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additivity hypothesis predicts the inactive drug should not contribute to the mixture effect. Thus, 
the equation for Zadd = Α/ρΑ. Zmix was calculated for each monkey as the total drug dose that 
decreased rates of responding to 50% of control or produced 50% MPE. Group mean Zmix and 
Zadd values were significantly different if the 95% confidence intervals did not overlap.  
 
Drugs 
 (−)-Oxycodone HCl was provided by the National Institute on Drug Abuse Drug Supply 
Program (Bethesda, MD). Racemic ketamine HCl was purchased from a commercial vendor as 
KetaVed© (Vedco, St. Joseph, MO). (−)-Nalbuphine HCl was provided by Dr. Kenner Rice 
(Drug Design and Synthesis Section, National Institute on Drug Abuse and National Institute on 
Alcohol Abuse and Alcoholism, Bethesda, MD). (+)-MK-801 hydrogen maleate was purchased 
from a commercial vendor (Sigma-Aldrich, St. Louis, MO). NMDA antagonists, mu-opioid 
agonists, and combination fixed proportions were dissolved in sterile water. Capsaicin (M2028; 
Sigma-Aldrich) was dissolved in a mixture of 70% ethanol (Pharmaco-AAPER, Brookfield, CT) 
and 30% sterile water no more than 30 minutes before use. Dissolved capsaicin was applied 
transdermally via an adhesive bandage measuring 2.5 x 8.3 cm (Band-Aid, Johnson and Johnson, 
New Brunswick, NJ). All drug doses were expressed as the salt forms listed above and 
administered intramuscularly into the thigh. 
 
RESULTS 
Mu-opioid agonist and ketamine interactions 
Assay of capsaicin-induced thermal allodynia 
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 The highest thermal stimulus that failed to elicit a tail-withdrawal response before 
capsaicin treatment was 42°C in two monkeys and 46°C in the other two monkeys throughout 
the study. Transdermal capsaicin application produced allodynia as indicated by reduced mean ± 
SEM tail withdrawal latencies at these temperatures to 2.5 ± 0.9 s, 2.0 ± 1.3 s, 2.5 ± 1.9 s, and 
1.5 ± 1.0 s at 15, 30, 45, and 60 min after capsaicin treatment, respectively. Nalbuphine, 
oxycodone, and ketamine produced dose-dependent antiallodynia (Figure 1A). The ED50 values 
and 95% confidence limits for each drug alone are shown in Tables 1 and 2. Based on these ED50 
values, three mixtures of nalbuphine + ketamine (1:3.3, 1:10, and 1:33 nalbuphine/ketamine) and 
oxycodone + ketamine (1:3.6, 1:10.7, and 1:32.1 oxycodone/ketamine) were examined. The dose 
ranges examined for each nalbuphine + ketamine mixture were 0.01-0.1 mg/kg nalbuphine 
(1:3.3), 0.01-0.1 mg/kg nalbuphine (1:10), and 0.01-0.056 mg/kg nalbuphine (1:33). The dose 
ranges examined for each oxycodone + ketamine mixture were 0.01-0.1 mg/kg oxycodone 
(1:3.6), 0.01-0.056 mg/kg oxycodone (1:10.7), and 0.0032-0.056 mg/kg oxycodone (1:32.1). 
Larger doses were not examined due to the emergence of undesirable effects (e.g. muscle tone 
loss) that impaired the monkey’s ability to maintain a sufficiently sternal posture in the chair. 
Tables 1 and 2 also show the ED50 values for each drug in each mixture, and Table 3 shows the 
predicted Zadd and experimentally determined Zmix values for nalbuphine/ketamine and 
oxycodone/ketamine mixtures. The dose-effect functions for nalbuphine/ketamine and 
oxycodone/ketamine mixtures are shown in Figure panels 2A and 3A, respectively. 
Isobolograms for both drug mixtures are shown in Figure panels 2C and 3C. Combining 
ketamine with either nalbuphine or oxycodone did not significantly alter the potency of either mu 
agonist to produce antiallodynia; however, ED50 values were only able to be determined in 2 out 
of 3 monkeys with the 1:10 and 1:33 nalbuphine/ketamine mixtures and the 1:32.1 
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oxycodone/ketamine mixture. For nalbuphine and ketamine mixtures, the 1:3.3 and 1:10 
mixtures produced additive effects. In the two monkeys that an ED50 value could be determined 
with the 1:33 nalbuphine/ketamine mixture, the effects were sub-additive. All oxycodone and 
ketamine mixtures produced antiallodynia effects consistent with additivity. 
 
Assay of Schedule-Controlled Responding 
 The average ± SEM control response rate throughout the entire study was 2.5 ± 0.1 
responses/s. Nalbuphine, oxycodone, and ketamine dose-dependently decreased rates of 
responding (Figure 1B). The ED50 values and 95% confidence limits for each drug are shown in 
Tables 1 and 2. Based on the relative potencies in the assay of capsaicin-induced thermal 
allodynia, the same three mixtures of nalbuphine + ketamine (1:3.3, 1:10, and 1:33 
nalbuphine/ketamine) and oxycodone + ketamine (1:3.6, 1:10.7, and 1:32.1 
oxycodone/ketamine) were examined. The dose ranges examined for each nalbuphine + 
ketamine mixture were 0.01-1 mg/kg nalbuphine (1:3.3), 0.01-0.32 mg/kg nalbuphine (1:10), and 
0.0032-0.1 mg/kg nalbuphine (1:33). The dose ranges examined for each oxycodone + ketamine 
mixture were 0.01-1 mg/kg oxycodone (1:3.6), 0.01-0.32 mg/kg oxycodone (1:10.7), and 
0.0032-0.1 mg/kg oxycodone (1:32.1). The dose-effect functions for nalbuphine/ketamine and 
oxycodone/ketamine mixtures are shown in Figure panels 2B and 3B, respectively. Isobolograms 
are shown in Figure panels 2D and 3D. Tables 1 and 2 also show the ED50 values for each drug 
in each mixture, and Table 3 shows the predicted Zadd and experimentally determined Zmix 
values for the nalbuphine/ketamine and oxycodone/ketamine mixtures, respectively. Increasing 
fixed proportions of ketamine enhanced the potency of nalbuphine to decrease rates of 
responding as demonstrated by the 95% confidence limits for the potency ratios not including 
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one. Dose-addition analysis demonstrated that all nalbuphine/ketamine mixtures produced 
additive effects. For oxycodone and ketamine mixtures, fixed proportions of 1:10.7 and 1:32.1 
increased the potency of oxycodone to decrease rates of responding compared to oxycodone 
alone. Dose-addition analysis demonstrated the 1:3.6 and 1:10.7 oxycodone/ketamine mixtures 
produced sub-additive effects; whereas the 1:32.1 oxycodone/ketamine mixture produced 
additive effects.  
 
Oxycodone and MK-801 interactions 
Assay of capsaicin-induced thermal allodynia 
Oxycodone alone produced dose-dependent antiallodynia, whereas MK-801 produced a 
maximum %MPE of 22.7 ± 17.8 at a dose of 0.032 mg/kg (Figure 1A). The ED50 values and 
95% confidence limits for oxycodone alone and each drug in the drug mixture are shown in 
Table 4. Because MK-801 produced > 50%MPE in only one subject, the relative potencies were 
based on the ED50 values in the assay of schedule-controlled responding (below). The dose 
ranges examined for all oxycodone + MK-801 mixtures were 0.01-0.32 mg/kg oxycodone and 
larger doses were not examined due to the emergence of undesirable effects (e.g. muscle tone 
loss) that impaired the monkey’s ability to maintain a sufficiently sternal posture in the chair. 
The dose-effect functions for oxycodone/MK-801 mixtures are shown in Figure panels 4A. The 
isobologram for the three oxycodone + MK-801 mixtures are shown in Figure 4C. Increasing 
fixed proportions of MK-801 did not significantly alter the potency of oxycodone to produce 
antiallodynia (Table 4). Table 5 shows the predicted Zadd and experimentally determined Zmix 
values for the oxycodone/MK-801 mixtures. The 1:0.028 and 1:0.085 oxycodone/MK-801 
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mixture produced effects consistent with additivity, whereas the 1:0.25 oxycodone/MK-801 
mixtures produced significant sub-additive effects. 
 
Assay of Schedule-Controlled Responding 
 Oxycodone and MK-801 alone produced dose-dependent decreases in rates of responding 
(Figure 1B). The ED50 values and 95% confidence limits for each drug are shown in Table 4, and 
based on the relative potencies, three mixtures of oxycodone + MK-801 (1:0.028, 1:0.085, and 
1:0.25 oxycodone/MK-801) were examined. The dose ranges examined for each oxycodone + 
MK-801 mixture were 0.01-1 mg/kg oxycodone (1:0.028), 0.01-0.56 mg/kg oxycodone 
(1:0.085), and 0.01-0.32 mg/kg oxycodone (1:0.25). The dose-effect functions for 
oxycodone/MK-801 mixtures are shown in Figure panel 4B. The isobologram for all three 
oxycodone + MK-801 mixtures are shown in Figure 4D. Fixed proportions (0.028 and 0.25) of 
MK-801 significantly enhanced the potency of oxycodone to decrease rates of responding (Table 
4). Table 5 shows the predicted Zadd and experimentally determined Zmix values for each drug 
mixture. All oxycodone and MK-801 mixtures produced effects consistent with additivity.  
  
Time Course Analysis 
 Figure 5 shows the time course of nalbuphine, oxycodone, ketamine, and MK-801 in the 
assay of schedule-controlled responding. Two-way repeated-measures analysis of variance 
demonstrated a significant main effect of time (F3,6=164.9, p<0.0001), drug (F4,8=28.9, 
p<0.0001), and drug × time interaction (F12,24=8.5, p<0.0001). All four drugs produced 
significant and peak rate-decreasing effects within 10-30 min post administration. MK-801 did 
produce rate-decreasing effects that were significantly different from oxycodone and ketamine, 
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but not nalbuphine, at the 30-min time point. Nalbuphine and MK-801 produced rate-decreasing 
effects that persisted to at least 100 min and were significantly longer than oxycodone and 
ketamine.  
 
DISCUSSION 
 This study assessed interactions between the noncompetitive NMDA antagonists racemic 
ketamine and (+)-MK-801 and the low-efficacy mu agonist nalbuphine and the moderate-
efficacy mu agonist oxycodone in assays of capsaicin-induced thermal allodynia and schedule-
controlled responding in rhesus monkeys. The main finding was that both racemic ketamine and 
(+)-MK-801 failed to enhance the antiallodynic effects of nalbuphine and oxycodone. 
Furthermore, ketamine selectively enhanced the potency of both nalbuphine and oxycodone to 
produce rate suppression. Overall, these preclinical results in monkeys do not support further 
consideration of noncompetitive NMDA antagonists as clinically useful adjuncts to mu-opioid 
agonists for the treatment of pain states associated with thermal hypersensitivity.  
 
Effects of Mu agonists and NMDA antagonists alone 
 Consistent with previous studies in rodents (Emery et al., 2017), nonhuman primates 
(Banks et al., 2010b; Negus et al., 2012), and humans (Watson and Babul, 1998; Hoeben et al., 
2012), both nalbuphine and oxycodone produced dose-dependent antiallodynia. Both nalbuphine 
and oxycodone dose-dependently decreased rates of operant responding and these nalbuphine 
results were consistent with previous nonhuman primate studies examining the rate-suppressant 
effects of mu-opioid agonists (Stevenson et al., 2003; Banks et al., 2010a). Furthermore, the 
present results extended these previous findings by determining the antiallodynic and rate-
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suppressant effects of the mu agonist oxycodone in nonhuman primates. Oxycodone was 
approximately 4 to 5-fold more potent to produce antiallodynia vs. rate suppression.  
 Although both ketamine and MK-801 produced dose-dependent decreases in rates of 
responding, only ketamine produced dose-dependent antiallodynia in the assay of capsaicin-
induced thermal allodynia. Both the rate-suppressant and antiallodynia effects of ketamine in the 
present study are consistent with previous results in rhesus monkeys (Butelman et al., 2003; 
Banks et al., 2010a). Furthermore, the present MK-801 results are consistent with a previous 
study in mice (Gewehr et al., 2011). In apparent contrast to the present results demonstrating 
MK-801 failed to produce antiallodynia, previous nonhuman primate studies have reported 
antiallodynic effects of MK-801 in an assay of capsaicin-induced thermal allodynia (Butelman et 
al., 2003) and antinociceptive effects in an assay of thermal nociception (France et al., 1989). 
However, the anti-allodynic effects of MK-801 were only present at a low thermal stimulus of 
38°C and MK-801 antiallodynic effects were more variable when the thermal stimulus was 
increased to 42°C (Butelman et al., 2003). In the present study, the baseline thermal intensities 
before capsaicin application were 42°C for two monkeys and 46°C for the other two monkeys. In 
the one monkey that did show an antiallodynic effect of MK-801, the baseline thermal intensity 
was 42°C. Another explanation for the differential ketamine and MK-801 results in the assay of 
capsaicin-induced thermal allodynia could be due to ketamine interacting with other receptor 
systems than NMDA. For example, racemic ketamine has been shown to have similar affinity for 
opioid receptors compared to the NMDA channel binding site (Hustveit et al., 1995). Overall, the 
general consistency of the present results with the published literature provided an empirical 
foundation to determine mu agonist and NMDA antagonist interactions.  
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Antiallodynia interactions 
 No fixed proportion of either NMDA antagonist selectively enhanced the antiallodynic 
effects of nalbuphine or oxycodone. The present additive antiallodynic results are consistent with 
ketamine and alfentanil analgesic interactions in humans using intradermal capsaicin (Sethna et 
al., 1998). Furthermore, the present additive or sub-additive interactions are consistent with and 
extend previous findings from our laboratory (Banks et al., 2010a) and others (Hoffmann et al., 
2003; Craft and Lee, 2005; Edwards et al., 2007; Haghparast et al., 2007; Pascual et al., 2010; 
Lilius et al., 2015) examining NMDA antagonist and mu-opioid agonist combinations in other 
preclinical assays of nociception, including allodynia. However, the present results may appear 
in contrast to previous studies in rodents demonstrating that NMDA antagonists enhance the 
antiallodynic/antihyperalgesic effects of mu agonists (Holtman Jr et al., 2008; Pascual et al., 
2010). There are two potential explanations for the differential results between the present study 
and these previous studies reporting an enhanced antinociceptive effect of the mu agonist.  
 First, drug interactions are not only dependent upon the relative dose, but also time 
course of each drug in a mixture. Thus, differences in mu agonist and NMDA antagonist time 
course could have influenced drug interactions when conducting fixed proportion interaction 
studies. This explanation seems unlikely for the following two reasons. First, peak rate 
decreasing effects were at 10 min for nalbuphine, oxycodone, and ketamine and 30 min for MK-
801 in the assay of schedule-controlled responding (Figure 5). Furthermore, all drugs produced 
significant rate-decreasing effects for at least 30 min, which was within the pretreatment time 
range used in assay of schedule-controlled responding. Second, statistical analyses did not 
demonstrate a significant main effect of time in the assay of capsaicin-induced thermal allodynia 
for any drug alone or drug mixture. Overall, these results suggest that modest differences in time 
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course between the drugs do not fully explain the absence of a selective NMDA antagonist 
enhancement of mu agonist antiallodynia.   
 Second, behavioral selectivity to produce antiallodynia vs. suppression of operant 
responding may also explain the differential results. Pain-stimulated behaviors, such as tail 
withdrawal, are highly susceptible to false positive results due to drug-induced motor 
impairment. In paclitaxel-treated rats, ketamine and morphine combinations produced an 
enhanced anti-thermal hyperalgesic effect, but no interaction on mechanical allodynia and no 
assessment of motor activity (Pascual et al., 2010). In a rat chronic constriction nerve injury 
model, the ketamine metabolite norketamine enhanced the antiallodynic and antihyperalgesic 
effects of morphine at dose combinations that did not significantly alter behavior in a rotorod or 
locomotor activity procedure (Holtman Jr et al., 2008). Moreover, a recent meta-analysis of 
ketamine and opioid use for pain reduction found that ketamine did not generally enhance pain 
relief produced by opioids (only 1 out of 6 showed an enhancement) and in fact, may enhance 
some undesirable neurological and psychological undesirable effects (Lee and Lee, 2016). 
Overall, the literature suggests that NMDA antagonists may selectively enhance the 
antiallodynic/antihyperalgesic effects of mu agonists over a narrow range of experimental 
conditions that depend upon not only the research subject species, but also the type of noxious 
stimulus and underlying physiological state.   
 
Comparison with other mu agonist interactions 
 The present mu agonist and NMDA antagonist interaction results can be compared to 
results that have determined fixed-proportion drug mixtures of other drug classes in combination 
with mu agonists under similar procedures. Two will be mentioned. First, the serotonin and 
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norepinephrine uptake inhibitor clomipramine selectively enhanced both the antiallodynic and 
antinociceptive vs. rate-suppressant effects of nalbuphine in monkeys (Banks et al., 2010b). 
Second, the delta-opioid agonist SNC80 has also selectively enhanced the antiallodynic and 
antinociceptive vs. rate-suppressant effects of nalbuphine in monkeys (Stevenson et al., 2003; 
Negus et al., 2012). In contrast, fixed proportions of NMDA antagonists and mu agonists have 
thus far failed to produce a selective enhancement of antinociception vs. rate suppression in both 
assays of capsaicin-induced thermal allodynia (present results) and warm water tail withdrawal 
(Banks et al., 2010a) and. Overall, this literature highlights the utility of the behavioral 
procedures described in the present study to examine mu agonist and other drug class 
interactions in the development of mu opioid adjuncts for the clinical treatment of various pain 
states. 
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Figure 1 
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Figure 2 
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Figure 3 
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Figure 4 
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Figure 5 
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FIGURE LEGENDS 
Figure 1: Potency of nalbuphine, oxycodone, ketamine, and MK-801 to produce anti-allodynia 
in an assay of capsaicin-induced thermal allodynia (Panel A; n=3-4) and decrease rates of 
responding in an assay of schedule-controlled responding (Panel B; n=3) in rhesus monkeys. Top 
abscissae: unit intramuscular (IM) drug dose in milligrams per kilogram (log scale). Top 
ordinate: percent maximum possible effect. Bottom abscissae: cumulative intramuscular (IM) 
drug dose in milligrams per kilogram (log scale). Bottom ordinate: percent control rate of 
responding. Each point shows mean ± SEM for 3-4 monkeys.  
 
Figure 2: Effects of the mu-opioid agonist nalbuphine alone or in combination with the 
noncompetitive NMDA antagonist ketamine on capsaicin-induced thermal allodynia (left panels) 
and rates of schedule-controlled responding (right panels). Top panels show dose-effect 
functions for nalbuphine alone or in combination with ketamine and bottom panels show 
isobolograms at the ED50 effect level for nalbuphine or ketamine alone or as part of a mixture. 
Top abscissae: unit nalbuphine dose (left panel) or cumulative nalbuphine dose (right panel) in 
milligrams per kilogram per injection. Top ordinates: percent control rate of responding. Bottom 
panels show isobolograms at the ED50 effect level for nalbuphine or ketamine alone or as part of 
a mixture. Bottom abscissae: ED50 values for nalbuphine alone or in a mixture in milligrams per 
kilogram (linear scale). Bottom ordinates: ED50 values for ketamine alone or in a mixture in 
milligrams per kilogram (linear scale). Each point represents mean ± SEM of 3-4 monkeys, 
except when noted by the number in parentheses. This denotes an experimental condition where 
an ED50 value could not be determined in all subjects tested.  
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Figure 3: Effects of the mu-opioid agonist oxycodone alone or in combination with the 
noncompetitive NMDA antagonist ketamine on capsaicin-induced thermal allodynia (left panels) 
and rates of schedule-controlled responding (right panels). Top panels show dose-effect 
functions for oxycodone alone or in combination with ketamine and bottom panels show 
isobolograms at the ED50 effect level for oxycodone or ketamine alone or as part of a mixture. 
Top abscissae: unit oxycodone dose (left panel) or cumulative oxycodone dose (right panel) in 
milligrams per kilogram per injection. Top ordinates: percent control rate of responding. Bottom 
panels show isobolograms at the ED50 effect level for oxycodone or ketamine alone or as part of 
a mixture. Bottom abscissae: ED50 values for oxycodone alone or in a mixture in milligrams per 
kilogram (linear scale). Bottom ordinates: ED50 values for ketamine alone or in a mixture in 
milligrams per kilogram (linear scale). Each point represents mean ± SEM of 3-4 monkeys. 
Asterisk indicates that the mixture produced a sub-additive effect in the assay of schedule-
controlled responding as determined by dose-addition analysis (see Table 3). 
 
Figure 4: Effects of the mu-opioid agonist oxycodone alone or in combination with the 
noncompetitive NMDA antagonist MK-801 on capsaicin-induced thermal allodynia (left panels) 
and rates of schedule-controlled responding (right panels). Top panels show dose-effect 
functions for oxycodone alone or in combination with MK-801 and bottom panels show 
isobolograms at the ED50 effect level for oxycodone or MK-801 alone or as part of a mixture. 
Top abscissae: unit oxycodone dose (left panel) or cumulative oxycodone dose (right panel) in 
milligrams per kilogram per injection. Top ordinates: percent control rate of responding. Bottom 
abscissae: ED50 values for oxycodone alone or in a mixture in milligrams per kilogram (linear 
scale). Bottom ordinates: ED50 values for MK-801 alone or in a mixture in milligrams per 
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kilogram (linear scale). Each point represents mean ± SEM of 3-4 monkeys. Asterisk indicates 
that the mixture produced a sub-additive effect in the assay of capsaicin-induced thermal 
allodynia as determined by dose-addition analysis (see Table 5).  
 
Figure 5: Time course of ED80 doses of nalbuphine (1.65 mg/kg), oxycodone (0.37 mg/kg), 
ketamine (1.41 mg/kg), and MK-801 (0.039 mg/kg) in an assay of schedule controlled 
responding in rhesus monkeys. Abscissa: time in min. post administration. Ordinate: percent 
control rate of responding. Each point represents the mean ± SEM of three rhesus monkeys. 
Filled symbols denote statistical significance (p<0.05) compared to vehicle. 
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Table 1:  ED50 values (95% confidence limits) for nalbuphine, oxycodone, and ketamine alone 
or in combination in assays of capsaicin-induced thermal allodynia and scheduled-controlled 
responding in rhesus monkeys. Numbers in parentheses denote the number of subjects 
contributing to the ED50 value if less than the total number of monkeys tested (n=3) and the > 
symbol denotes a drug mixture for which an ED50 value could not be determined in all subjects 
tested.  
Drug or drug mixture Nalbuphine 
ED50 (95% CL) 
Potency Ratio 
(95% CL) 
Ketamine 
ED50 (95% CL) 
Capsaicin-induced thermal 
allodynia 
   
Nalbuphine Alone 0.05 (0, 0.36)                   - 
Ketamine Alone                  -  0.53 (0.31, 0.91) 
1:3.3 Nalbuphine/Ketamine 0.03 (0.02, 0.04) 1.38 (-2.91, 
5.66) 
0.11 (0.08, 0.15) 
1:10 Nalbuphine/Ketamine (n=2) > 0.06 (0.03, 0.1)  > 0.65 (0.1, 4.15) 
1:33 Nalbuphine/Ketamine (n=2) > 0.04 (0, 0.17)  > 1.29 (0.07, 
24.12) 
Schedule-controlled responding    
Nalbuphine Alone 0.7 (0.25, 1.96)                  - 
Ketamine Alone                 -  0.86 (0.70, 1.06) 
1:3.3 Nalbuphine/Ketamine 0.18 (0.09, 0.35) 0.28 (-0.06, 
0.63)a 
0.59 (0.30, 1.16) 
1:10 Nalbuphine/Ketamine 0.12 (0.08, 0.17) 0.21 (-0.24, 1.15 (0.80, 1.67) 
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0.66)a 
1:33 Nalbuphine/Ketamine 0.04 (0.02, 0.06) 0.07 (-0.07, 
0.20)a  
1.12 (0.71, 1.79) 
 
a Potency shifts were considered statistically significant if the 95% confidence limits of the 
potency ratios did not include 1.  
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Table 2: ED50 values (95% confidence limits) for oxycodone and ketamine alone or in 
combination assays of capsaicin-induced thermal allodynia and scheduled-controlled responding 
and in rhesus monkeys. Numbers in parentheses denote the number of subjects contributing to 
the Zmix or Zadd values if less than the total number of monkeys tested (n=3) and the > symbol 
denotes a drug mixture for which an ED50 value could not be determined in all subjects tested. 
Drug or drug mixture Oxycodone  
ED50 (95% CL) 
Potency Ratio 
(95% CL) 
Ketamine 
ED50 (95% CL) 
Capsaicin-induced thermal 
allodynia 
   
Oxycodone Alone 0.05 (0.01, 0.2)                   - 
Ketamine Alone                  -  0.53 (0.31, 0.91) 
1:3.6 Oxycodone/Ketamine 0.03 (0.01, 0.17) 0.61 (-0.56, 1.78) 0.11 (0.05, 0.25) 
1:10.7 Oxycodone/Ketamine 0.04 (0.02, 0.07) 0.56 (0.11, 1.02) 0.38 (0.28, 0.51) 
1:32.1 Oxycodone/Ketamine 
(n=2) 
> 0.03 (0, 0.21)  > 0.82 (0.28, 2.39) 
Schedule-controlled responding    
Oxycodone Alone 0.25 (0.17, 0.37)                  - 
Ketamine Alone                 -  0.86 (0.70, 1.06) 
1:3.6 Oxycodone/Ketamine 0.21 (0.12, 0.36) 0.83 (0.44, 1.23) 0.75 (0.44, 1.28) 
1:10.7 Oxycodone/Ketamine 0.12 (0.08, 0.16) 0.47 (0.17, 0.76) a 1.24 (0.88, 1.75) 
1:32.1 Oxycodone/Ketamine 0.04 (0.02, 0.07) 0.17 (0, 0.34) a 1.29 (0.72, 2.31) 
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a Potency shifts were considered statistically significant if the 95% confidence limits of the 
potency ratios did not include 1. 
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Table 3: Experimentally determined Zmix values and predicted Zadd values (95% confidence 
limits) for mixtures of nalbuphine or oxycodone and ketamine in assays of capsaicin-induced 
thermal allodynia and schedule-controlled responding in rhesus monkeys. Numbers in 
parentheses denote the number of subjects contributing to the Zmix or Zadd values if less than 
the total number of monkeys tested (n=3) and denote a drug mixture for which an ED50 value 
could not be determined.  
Drug or drug mixture Zmix Zadd 
Capsaicin-induced thermal allodynia   
1:3.3 Nalbuphine/Ketamine 0.15 (0.13, 0.17) 0.19 (0.11, 0.34) 
1:10 Nalbuphine/Ketamine (n=2) 0.71 (0.53, 0.95) 0.33 (0.18, 0.61) 
1:33 Nalbuphine Ketamine (n=2) 1.33 (0.85, 2.1) a 0.43 (0.26, 0.71) 
1:3.6 Oxycodone/Ketamine 0.15 (0.07, 0.32) 0.17 (0.15, 0.20) 
1:10.7 Oxycodone/Ketamine 0.41 (0.31, 0.55) 0.25 (0.18, 0.35)  
1:32.1 Oxycodone/Ketamine (n=2) 0.84 (0.29, 2.45) 0.41 (0.28, 0.61) 
Schedule-controlled responding   
1:3.3 Nalbuphine/Ketamine 0.77 (0.40, 1.51) 0.80 (0.45, 1.45) 
1:10 Nalbuphine/Ketamine 1.27 (0.88, 1.84) 0.85 (0.64, 1.14) 
1:33 Nalbuphine/Ketamine 1.61 (0.73, 1.85) 0.87 (0.79, 0.95) 
1:3.6 Oxycodone/Ketamine 0.96 (0.57, 1.63) a 0.42 (0.39, 0.44) 
1:10.7 Oxycodone/Ketamine 1.36 (0.96, 1.91) a 0.57 (0.52, 0.62) 
1:32.1 Oxycodone/Ketamine 1.33 (0.74, 2.38) 0.71 (0.61, 0.84) 
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a Denotes Zmix confidence limits do not overlap with Zadd confidence limits: Zmix larger than 
Zadd indicating sub-additivity.  
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Table 4: ED50 values (95% confidence limits) for oxycodone and MK-801 alone or in 
combination assays of scheduled-controlled responding and capsaicin-induced thermal allodynia 
in rhesus monkeys.  
Drug or drug mixture Oxycodone  
ED50 (95% CL) 
Potency Ratio 
(95% CL) 
MK-801 
ED50 (95% CL) 
Capsaicin-induced thermal 
allodynia 
   
Oxycodone Alone 0.05 (0.04, 0.06)                   - 
MK-801 Alone                  -             Inactive 
1:0.028 Oxycodone/MK-801 0.13 (0.06, 0.3) 2.64 (-1.69, 
6.98) 
0.004 (0.002, 
0.008) 
1:0.085 Oxycodone/MK-801 0.13 (0.05, 0.32) 2.09 (-2.71, 6.9) 0.011 (0.004, 
0.027) 
1:0.25 Oxycodone/MK-801 0.17 (0.07, 0.4) 2.37 (-2.12, 
6.87) 
0.041 (0.017, 
0.099) 
Schedule-controlled responding    
Oxycodone Alone 0.27 (0.15, 0.51)                  - 
MK-801 Alone                 -  0.02 (0.02, 0.03) 
1:0.028 Oxycodone/MK-801 0.23 (0.12, 0.47) 0.86 (0.75, 
0.98) a 
0.01 (0.003, 
0.013) 
1:0.085 Oxycodone/MK-801 0.20 (0.12, 0.33) 0.74 (0.35, 
1.14) 
0.02 (0.01, 0.03) 
1:0.25 Oxycodone/MK-801 0.12 (0.05, 0.28) 0.45 (0.19, 0.03 (0.01, 0.07) 
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0.71) a 
 
a Potency shifts were considered statistically significant if the 95% confidence limits of the 
potency ratios did not include 1. 
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Table 5: Experimentally determined Zmix values and predicted Zadd values (95% confidence 
limits) for mixtures of oxycodone and MK-801 in assays of capsaicin-induced thermal allodynia 
and schedule-controlled responding in rhesus monkeys.  
Drug or drug mixture Zmix Zadd 
Capsaicin-induced thermal allodynia   
1:0.028 Oxycodone/MK-801 0.14 (0.08, 0.23) 0.06 (0.05, 0.08) 
1:0.085 Oxycodone/MK-801 0.14 (0.08, 0.24)  0.06 (0.05, 0.08) 
1:0.25 Oxycodone/MK-801 0.21 (0.12, 0.35) a 0.07 (0.06, 0.09) 
Schedule-controlled responding   
1:0.028 Oxycodone/MK-801 0.24 (0.12, 0.48) 0.21 (0.12, 0.39) 
1:0.085 Oxycodone/MK-801 0.22 (0.13, 0.36) 0.15 (0.09, 0.26) 
1:0.25 oxycodone/MK-801 0.15 (0.07, 0.35) 0.09 (0.06, 0.14) 
 
a Denotes Zmix confidence limits do not overlap with Zadd confidence limits: Zmix larger than 
Zadd indicating sub-additivity.  
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Chapter 3: Identifying potential pharmacological determinants of the antinociceptive interaction 
between the NOP receptor agonist adjunct, Ro 64-6198, and MOR agonists in male rhesus 
monkeys. 
 
1. INTRODUCTION  
Pain management remains a significant public health issue in the United States 
(Ballantyne et al, 2017). Mu-opioid receptor agonists (e.g. oxycodone) are one of the most 
effective pharmacological tools available to clinicians for the treatment of pain (Dowell and 
Haegerich, 2016). However, the clinical utility of mu-opioid agonists is severely limited by a 
number of undesirable effects including respiratory depression and sedation. One approach to 
enhance the clinical utility of mu-opioid agonists may be to combine them with other compounds 
that act through different receptor mechanisms (Di Cesare Mannelli et al., 2015; Dietis et al., 
2009; Gunther et al., 2017).  
One potential receptor system that might function as a useful mu-opioid agonist adjunct 
is the nociceptin opioid peptide (NOP) system. Two lines of evidence support potential 
interactions between mu-opioid and NOP receptors. First, NOP receptors are colocalized with 
mu-opioid receptors in both spinal and brain regions involved in nociceptive signaling pathways 
(for review, see Toll et al. 2016). Second, preclinical studies have reported species difference in 
the antinociceptive effects of the selective high-efficacy NOP agonist Ro 64-6198 (Jenck et al., 
2000). For example, systemic Ro 64-6198 produced antinociception in monkeys (Ko et al., 
2009), but not rodents (Reiss et al., 2008). Further highlighting potential species differences, 
systemic combinations of Ro 64-6198 and a mu-opioid agonist produced additive antinociceptive 
effects in mice (Reiss et al., 2008), but synergistic antinociceptive effects in rhesus monkeys 
 
64 
(Cremeans et al., 2012). Overall, this literature supports further evaluation of NOP and mu-
opioid agonist interactions.  
Previous studies examining mu-opioid agonist antinociceptive interactions with other 
receptor systems suggest that one important determinant of these interactions may be MOR 
agonist efficacy (Banks et al., 2010b; Maguire and France, 2014; Negus et al., 2009). However, 
the degree to which mu-opioid agonist efficacy is a determinant of NOP agonist interactions is 
unknown. Therefore, the aim of the present study was to determine the role of mu-opioid ligand 
efficacy in antinociceptive interactions with the NOP agonist Ro 64-6198 in rhesus monkeys 
using previously described procedures (Banks et al., 2010b; Stevenson et al., 2003). 
Antinociceptive interactions between Ro 64-6198 and six mu-opioid ligands (17-
cyclopropylmethyl- 3,14β-dihyroxy-4,5α-epoxy-6α-[(3 ́-isoquinolyl)acetamindo]morphinan 
(NAQ), buprenorphine, nalbuphine, morphine, oxycodone, and methadone) that vary in agonist-
stimulated GTPγS binding from lowest to highest (Selley et al., 1998; Thompson et al., 2004; 
Zaidi et al., 2013) and in their in vivo effectiveness to produce antinociception (Cornelissen et 
al., 2018a) were investigated. For comparison, Ro 64-6198 interactions were also investigated 
with the selective high efficacy kappa-opioid receptor agonist nalfurafine. Nalfurafine is not a 
clinically-approved analgesic and fails to produce antinociception under conditions that 
dissociate antinociception from behavioral sedation (Endoh et al., 2001; Lazenka et al., 2018). 
Drug interactions were also examined in an assay of schedule-controlled responding in a 
different cohort of monkeys to assess behavioral selectivity to produce antinociception vs. rate 
suppression. If NOP agonists are to be considered as candidate mu-opioid agonist adjuncts, then 
we would hypothesize that Ro 64-6198 would robustly and selectively enhance the 
antinociceptive vs. rate-suppressant effects of mu-opioid agonists. 
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2. MATERIALS AND METHODS  
2.1 Subjects 
A total of seven middle-aged adult (10-18 years old) male rhesus macaques (Macaca 
mulatta) of either Indian or Chinese origin and weighing between 10-14 kg served as subjects. 
Four monkeys served as subjects in the assay of thermal nociception, and three monkeys served 
as subjects in the assay of schedule-controlled responding. These sample sizes have been 
sufficient to detect mu-opioid agonist interactions in previous publications (Banks et al., 2010a; 
Banks et al., 2010b; Maguire and France, 2014; Schwienteck et al., 2018; Stevenson et al., 
2003). All monkeys had experimental histories of opioid, monoamine transporter ligand, and N-
methyl D-aspartate antagonist exposure. Diet was comprised of laboratory monkey chow (#5049, 
Purina, Framingham, MA) and supplemented with fresh fruits, vegetables, and nuts. All subjects 
were housed individually and had ad lib water access while in the housing chamber. A 12h 
light/dark cycle (lights on from 6:00 AM to 6:00 PM) was in effect. Housing facilities were 
licensed by the United States Department of Agriculture and accredited by AAALAC 
International. The VCU Institutional Animal Care and Use Committee approved all research and 
enrichment protocols in accordance with the 2011 Guide for the Care and Use of Laboratory 
Animals.  
 
2.2 Assay of Thermal Nociception 
Monkeys were trained to sit comfortably in an acrylic restraint chair using the pole-and-
collar technique such that their tails hung freely. The subject’s tail was shaved 10-12 cm from 
the distal end weekly and immersed in a thermal container of warm water. If the subject did not 
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remove its tail by 20 s, the experimenter removed the tail and a latency of 20 s was assigned. A 
stopwatch was utilized to record tail-withdrawal latencies. During each 15-min cycle, tail-
withdrawal latencies were recorded from water warmed to 38°C, 50°C, and 54°C and the order 
of warmed water presentations was counterbalanced between successive cycles. Baseline tail-
withdrawal latencies at all three thermal intensities were determined in each daily test session 
before drug administration. Test sessions continued only if tail-withdrawal latencies from 38°C 
water did not occur before the 20 s cutoff. This criterion was met in every monkey during every 
test session. Time course test sessions consisted of a single drug dose administered 
intramuscularly (IM) and tail withdrawal latencies were re-determined at 10, 30, and 100 min 
post-drug administration. Cumulative dose test sessions consisted of four to five 15-minute 
cycles composed of a 10-minute drug pretreatment phase and a 5-min testing phase. Drugs were 
administered IM at the start of each 15-min cycle, and each drug dose increased the total 
cumulative dose by one-fourth or one-half log units. Tail-withdrawal latencies were re-
determined during the 5-min testing phase as described above.  
Initially, the time course of (−)-Ro 64-6198 (0.1 and 0.32 mg/kg) and SB-612111 (0.32 
mg/kg) were singly determined. Following these initial Ro 64-6198 time-course experiments, 
two additional experiments were conducted. First, the effectiveness of Ro 64-6198 to alter the 
antinociceptive effects of 6 mu-opioid ligands and the kappa-opioid agonist nalfurafine was 
determined. Cumulative dose-effect functions for NAQ (0.1-3.2 mg/kg), buprenorphine (0.032-1 
mg/kg), nalbuphine (0.032-3.2 mg/kg), morphine (0.1-10 mg/kg), oxycodone (0.01-1 mg/kg), 
methadone (0.1-5.6 mg/kg), and nalfurafine (0.0001-0.01 mg/kg) were determined following a 
30-min pretreatment of 0.1 mg/kg Ro 64-6198 or vehicle. Mu-opioid ligands were tested up to 
doses that produced maximal antinociception, undesirable effects such as respiratory depression, 
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or reached solubility limits. Nalfurafine was tested up to doses that produced emesis. These 
experiments were generally conducted twice per week, except for studies with buprenorphine, 
nalbuphine, and nalfurafine, which were separated by at least 6 days to allow dissipation of long-
acting drug effects and/or to minimize potential effects of antinociceptive tolerance. Ro 64-6198 
test sessions were also separated by at least 7 days. Second, potency, time course, and 
antagonism of Ro 64-6198 enhancement of nalbuphine-induced antinociception were determined 
in three of the four monkeys used for the mu-opioid ligand and Ro 64-6198 interactions 
described above. One monkey was removed from this set of experiments due to health issues 
unrelated to the study. These experiments were also separated by at least 7 days. The 
experimenter was not blinded to drug or dose conditions due to potential animal health issues 
when evaluating novel drug interactions consistent with our previous publications (Banks et al., 
2010a; Banks et al., 2010b; Cornelissen et al., 2018a). Ro 64-6198 and vehicle pretreatments 
were counterbalanced between opioid ligands, but pretreatments were consistent across all 
monkeys. 
 
2.3 Assay of Schedule-Controlled Responding 
Experiments were conducted in each monkey’s housing chamber, which also served as 
the experimental chamber as previously described (Banks et al., 2010b). A custom-fabricated 
operant response panel and a food pellet dispenser (Med Associates, ENV-203-1000, St. Albans, 
VT) were attached to the front of the housing chamber. Panels were operated under a MED-PC 
interface and programmed with a Windows-based computer using MEDSTATE Notation (MED 
Associates). Training sessions were composed of five 15-min cycles for a total session duration 
of 75 min. Two components were incorporated into each cycle. The first component was a 10-
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min time-out period during which responses had no scheduled consequences. The second 
component was a 5-min response period during which the right key was transilluminated red, 
and subjects could respond under a fixed-ratio 30 (FR30) schedule of food pellet presentation. If 
a subject earned the maximum of 10 pellets prior to completion of the 5-min period, the response 
component was terminated, stimulus lights were extinguished, and further responses resulted in 
no consequences. All monkeys were trained until rates of responding were ≥ 1.0 response/s 
during all 5 cycles for 7 consecutive days (data not shown).  
Behavioral sessions were conducted 5 days per week. Training sessions were conducted 
on Mondays, Wednesdays, and Thursdays, and test sessions were conducted on Tuesdays and 
Fridays. Subjects were eligible for participation in test sessions if rates of operant responding 
were ≥ 1.0 response/s on training days that preceded test days. On test days, test compounds 
were administered IM using the same cumulative dosing procedure described above in the assay 
of thermal nociception. All drugs and pretreatment combinations were tested up to doses that 
either decreased responding >70% of the preceding training day’s average response rate or 
reached solubility limits. Individual test sessions lasted for 3 to 6 cycles depending on individual 
subject behavior and treatment condition.  
Initially, the potency and time course of vehicle, (−)-Ro 64-6198 (0.1-0.32 mg/kg), and 
SB- 612111 (0.32 mg/kg) were determined. Additionally, the effectiveness of SB-612111 to 
antagonize the rate-decreasing effects of Ro 64-6198 was evaluated. Subsequently, Ro 64-6198 
interactions with the same opioid ligands evaluated in the assay of thermal nociception were 
determined. Cumulative dose-effect functions for NAQ (0.1-10 mg/kg), buprenorphine (0.032-
3.2 mg/kg), nalbuphine (0.032-1 mg/kg), morphine (0.1-5.6 mg/kg), oxycodone (0.01-1.0 
mg/kg), methadone (0.1-3.2 mg/kg), and nalfurafine (0.0001-0.0032 mg/kg), were determined 
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following a 30-min pretreatment of 0.1 mg/kg Ro 64-6198 or vehicle. These experiments were 
generally conducted twice per week, except for studies with buprenorphine, nalbuphine, and 
nalfurafine, which were separated by at least 7 days to allow dissipation of long-acting drug 
effects and/or to minimize potential tolerance to the rate-decreasing effects of low efficacy mu-
opioid ligands. Ro 64-6198 test sessions were also separated by at least 7 days. Ro 64-6198 and 
vehicle pretreatments were counterbalanced between opioid ligands, but pretreatments were 
consistent across all monkeys. 
 
2.4 Data Analysis  
For the assay of thermal nociception, tail-withdrawal latencies (in sec) were converted to 
percent maximal possible effect (%MPE). %MPE was defined as {(Test latency – Control 
latency) ÷ (20 – Control Latency) * 100} where “test latency” was the latency in response to 
either 50°C or 54°C at each dose during the cumulative dosing procedure, and “control latency” 
was the latency in response to either 50°C or 54°C taken during the baseline period prior to drug 
administration. Statistical analysis of all %MPE data was conducted using a repeated-measures 
two-way ANOVA with either time or pretreatment and opioid ligand dose as the main factors 
(all factors repeated measures). A Sidak or Tukey post-hoc test, as appropriate, followed all 
significant interactions. Significance was set a priori at the 95% confidence level.  
For the assay of schedule-controlled responding, rates of operant responding 
(responses/sec) during each test cycle were converted to percent control rate using the average 
rate of responding of the 5 cycles from the individual monkey’s previous training session. 
Statistical analysis of all % control data was conducted using a repeated-measures two-way 
ANOVA with either time or pretreatment and opioid ligand dose as the main factors (all factors 
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repeated measures). A Sidak or Tukey post-hoc test, as appropriate, followed all significant 
interactions.   
In addition, the effective dose (ED50) that produced either 50%MPE or 50% reduction in 
control rates of responding was determined for each mu-opioid ligand and nalfurafine following 
0.1 mg/kg Ro 64-6198 or vehicle pretreatment. ED50 values were determined by interpolation 
when only 2 data points were available (one below and one >50% effect) or by linear regression 
when at least 3 data points on the linear portion of the dose-effect function were available as 
previously described (Banks et al., 2010b; Cornelissen et al., 2018a; Cornelissen et al., 2018b; 
Stevenson et al., 2003). Individual ED50 values were subsequently averaged to yield group mean 
ED50 values and 95% confidence intervals using the Student’s T distribution (confidence.t 
equation in Microsoft Excel for Mac, Version 16.9, Microsoft, Redmond, WA).  
 
2.5 Drugs 
(±)-Methadone HCl and (±)-buprenorphine HCl were purchased from a commercial 
supplier (Spectrum Chemicals, Gardena, CA). (−)-Oxycodone HCl, (−)-morphine sulfate, (−)-
nalfurafine HCl, (−)-Ro 64-6198 HCl, and SB-612111 HCl were supplied by the National 
Institute on Drug Abuse Drug Supply Program (Bethesda, MD). (−)-Nalbuphine HCl was 
supplied by Dr. Kenner Rice (Drug Design and Synthesis Section, National Institute on Drug 
Abuse and National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD). NAQ HCl was 
synthesized as previously described (Li et al., 2009) and supplied by Drs. Samuel Obeng and 
Yan Zhang. Buprenorphine, nalbuphine, oxycodone, morphine, methadone, and nalfurafine were 
dissolved in sterile water. (−)-Ro 64-6198 was dissolved in a solution of 1:4:5 Tween 80 
(Spectrum Chemicals, Gardena, CA) to dimethyl sulfoxide (DMSO) (Sigma-Aldrich, St. Louis, 
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MO) to sterile water. SB-612111 was dissolved in a solution of 4:6 DMSO to sterile water. NAQ 
was dissolved in a solution of 3:7 DMSO to sterile water. All drug doses were administered 
intramuscularly and expressed as the salt forms listed above.  
 
3. RESULTS  
3.1 Effects of Ro 64-6198 alone 
Average ± S.E.M. baseline tail withdrawal latencies for Ro 64-6198 alone and in 
combination with various mu-opioid ligand experiments were 1.0 ± 0.4 s at 50°C and 0.7 ± 0.1 s 
at 54°C. Average control rates of responding across all experiments was 2.5 ± 0.4 responses/s. 
Fig. 1 shows the potency and time course of Ro 64-6198 alone to produce antinociception 
(panels A and B) and rate-suppression (panel C). Up to 0.32 mg/kg, Ro 64-6198 did not produce 
significant antinociception with a maximum %MPE of 9.4 ± 7.4 and 1.1 ± 0.8 at 50 and 54°C, 
respectively. In contrast, Ro 64-6198 produced dose- and time-dependent decreases in rates of 
responding with maximal effects at 100 min following 0.32 mg/kg administration (treatment: 
F4,8=16.2, P<0.05; time: F3,6=18.8, P<0.05; interaction: F12,24=2.9, P<0.05). The rate-decreasing 
effects of Ro 64-6198 were blocked by the NOP antagonist SB-612111 at a dose (0.32 mg/kg) 
that had no effect on rates of responding alone. Larger Ro 64-6198 doses (1.0 mg/kg) were 
evaluated, but required prompt SB-612111 administration due to the emergence of undesirable 
effects including loss of muscle tone and slowed respiratory rate.  
 
3.2 Effects of Ro 64-6198 pretreatment on mu-opioid ligand-induced antinociception 
Fig. 2 shows the antinociceptive effects of NAQ, buprenorphine, nalbuphine, morphine, 
oxycodone, and methadone following either vehicle or 0.1 mg/kg Ro 64-6198 pretreatment. 
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Buprenorphine, nalbuphine, morphine, oxycodone, and methadone produced dose-dependent 
antinociception at 50°C under vehicle conditions and the corresponding ED50 values for each 
mu-opioid agonist are reported in Table 1. NAQ produced a group mean ± S.E.M. maximum 
%MPE of 4.9±5.1 at 50°C (Fig. 2, panel A). Supplemental Fig. 1 also shows the antinociceptive 
effects of these same mu-opioid ligands alone at a higher thermal intensity (54°C). Only 
morphine, oxycodone, and methadone produced > 50%MPE at 54°C and the corresponding ED50 
values are reported in Supplemental Table 1. NAQ, buprenorphine, and nalbuphine produced a 
maximum %MPE of 1.1±1.9, 9.3±6.9, and 37.2±7.3 at 54°C, respectively (Supplemental Table 
1).  
Pretreatment with a Ro 64-6198 dose (0.1 mg/kg) that was ineffective alone significantly 
enhanced the antinociceptive effects of buprenorphine (dose: F2,6= 29.4, P<0.05; pretreatment: 
F1,3=17.4, P<0.05; interaction: F2,6=17.0, P<0.05), nalbuphine (dose: F4,12= 489, P<0.05; 
pretreatment: F1,3=79.3, P<0.05; interaction: F4,12=19.8, P<0.05), and methadone (dose: 
F4,12=56.6, P<0.05; interaction: F4,12=4.2, P<0.05) at 50°C (Fig. 2). The corresponding ED50 
values of each mu-opioid agonist following Ro 64-6198 pretreatment are also reported in Table 
1. Post-hoc power analyses indicated the morphine (power=0.65) and oxycodone (power=0.67) 
experiments were underpowered to detect a significant interaction between Ro 64-6198 and these 
two mu-opioid agonists. At the 54°C thermal stimulus, Ro 64-6198 pretreatment also 
significantly enhanced the antinociceptive effects of methadone (methadone dose: F4,12=657, 
P<0.05; pretreatment: F1,3=146.4, P<0.05; interaction: F4,12= 65.1, P<0.05). The corresponding 
ED50 values for methadone and the other mu-opioid agonists at 54°C are also reported in 
Supplemental Table 1. 
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3.3 Effects of Ro 64-6198 pretreatment on mu-opioid ligand-induced rate-suppression 
Fig. 3 shows the effects of NAQ, buprenorphine, nalbuphine, morphine, oxycodone, and 
methadone on rates of responding following either vehicle or 0.1 mg/kg Ro 64-6198 
pretreatment. NAQ and buprenorphine alone did not significantly alter rates of responding up to 
the largest doses tested and maximal rate-decreasing effects (mean ± S.E.M.) were 87.4 ± 27.9% 
and 64.9 ± 20.8% control, respectively (Fig. 3). Larger NAQ and buprenorphine doses could not 
be examined due to solubility limits. However, NAQ and buprenorphine were tested up to doses 
that antagonized the antinociceptive effects of other mu-opioid agonists (Cornelissen et al., 
2018a; Walker et al., 1995). Nalbuphine, morphine, oxycodone, and methadone alone all 
produced dose-dependent decreases in rates of responding and the corresponding ED50 values are 
shown in Table 1. Ro 64-6198 pretreatment did not enhance the effectiveness of NAQ or 
buprenorphine to alter rates of responding (Fig. 3). Ro 64-6198 pretreatment also did not 
enhance the potency of nalbuphine, morphine, oxycodone, or methadone to decrease rates of 
responding as denoted by overlapping confidence limits for ED50 values (Table 1).  
 
3.4 Effects of Ro 64-6198 pretreatment on nalfurafine-induced antinociception and rate-
suppression 
 Fig. 4 shows the antinociceptive (A) and rate-altering (B) effects of nalfurafine following 
either vehicle or 0.1 mg/kg Ro 64-6198 pretreatment. Nalfurafine alone failed to produce 
antinociception up to the highest dose tested with maximal effects (mean ± S.E.M.) of 9.1 ± 10.7 
% and 6.8 ± 2.9 % at 50 and 54°C, respectively (Fig. 4 panels A and B). Ro 64-6198 enhanced 
the antinociceptive effects of nalfurafine at 50°C (nalfurafine dose: F4,8=4.7, P<0.05; interaction: 
F4,8= 4.8, P<0.05) (Fig. 4 panel A). Nalfurafine alone produced dose- and time- dependent 
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decreases in rates of responding and the corresponding ED50 values are shown in Table 1. Time 
course of nalfurafine rate-decreasing effects are shown in Supplemental Fig. 2. Ro 64-6198 
pretreatment attenuated the effectiveness of cumulative 0.001 mg/kg nalfurafine to decrease rates 
of responding (nalfurafine dose: F3,6=11.7, P<0.05; interaction: F3,6= 8.9, P<0.05). Ro 64-6198 
did not alter nalfurafine potency to decrease rates of responding (Table 1). 
 
3.5 Potency, time course, and antagonism of Ro 64-6198 enhancement of nalbuphine 
antinociception  
Fig. 5 shows the potency (A), time course (B), and sensitivity to NOP antagonism (C) of 
Ro 64-6198 enhancement of nalbuphine antinociception at 50°C. For these experiments, group 
mean ± S.E.M. baseline tail withdrawal latencies were 0.8 ± 0.3 s at 50°C and 0.8 ± 0.2 s at 
54°C. There was no significant effect of Ro 64-6198 on nalbuphine effects at 54°C (data not 
shown). Similar to results in Fig. 2, 0.1 mg/kg Ro 64-6198, but not 0.032 mg/kg, enhanced 
nalbuphine antinociception (nalbuphine dose: F4,8=39.3, P<0.05; Ro 64-6198 dose: F2,4= 12.1, 
P<0.05; interaction: F8,16= 8.3, P<0.05) (Fig. 5 panel A). In addition, only the 30-min 
pretreatment time was sufficient for Ro 64-6198 to enhance the antinociceptive effects of 
nalbuphine (time: F3,6=6.3, P<0.05; nalbuphine dose: F4,8=61.3, P<0.05; interaction: F12,24=6.8, 
P<0.05) (Fig. 5 panel B). Finally, Ro 64-6198 enhancement of nalbuphine antinociception was 
blocked by the NOP antagonist SB-612111 (nalbuphine dose: F4,8=53.5, P<0.05; pretreatment: 
F3,6=11.7, P=0.05; interaction: F12,24=9.3, P<0.05) (Fig. 5 panel C). SB-612111 (0.32 mg/kg) 
pretreatment also significantly attenuated the antinociceptive effects of the 0.32 mg/kg 
cumulative nalbuphine dose (Fig. 5 panel C).  
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4. DISCUSSION  
4.1 Conclusions 
The present study determined whether mu-opioid ligand efficacy was a determinant of 
antinociceptive interactions with the NOP agonist (−)-Ro 64-6198 in rhesus monkeys. There 
were three main findings. First, both Ro 64-6198 and nalfurafine were more potent to decrease 
rates of responding than produce antinociception. Second, Ro 64-6198 enhanced the 
antinociceptive potency of buprenorphine, nalbuphine, and methadone suggesting that mu-opioid 
agonist efficacy was not a determinant of mu-opioid and NOP agonist interactions. Despite, Ro 
64-6198 and mu-opioid agonist interactions displaying some degree of behavioral selectivity, Ro 
64-6198 enhancement of mu-agonist antinociception occurred under a narrow range of 
experimental conditions. Lastly, NOP agonist interactions were not selective for mu-opioid 
agonists because Ro 64-6198 also enhanced the antinociceptive effects of the kappa-opioid 
agonist nalfurafine. Collectively, these results dampen enthusiasm for NOP agonists as candidate 
“opioid-sparing” adjuncts.  
 
4.2 Effects of Ro 64-6198, mu-opioid agonists, and nalfurafine alone  
The mu-opioid agonists buprenorphine, nalbuphine, morphine, oxycodone, and 
methadone produced dose- and noxious stimulus- dependent antinociception consistent with the 
extant literature (Cornelissen et al., 2018a; Gatch et al., 1998; Maguire and France, 2014; Walker 
et al., 1993). Nalfurafine failed to produce antinociception up to a 3-fold larger dose than doses 
that suppressed rates of responding. Although nalfurafine has been previously shown to produce 
antinociception in a warm water tail-withdrawal procedure in monkeys (Endoh et al., 2001; Ko 
and Naughton, 2009), nalfurafine-induced antinociception in these previous studies occurred at 
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doses larger than those that maximally decreased rates of responding in the present study. The 
NOP agonist Ro 64-6198 also did not produce antinociception up to doses that significantly 
decreased rates of responding. These results were consistent with a previous monkey study 
(Saccone et al., 2016), but inconsistent with other monkey studies (Cremeans et al., 2012; Ko et 
al., 2009; Podlesnik et al., 2011). Reasons for the inconsistent NOP agonist antinociceptive 
effects in monkeys are not entirely clear and highlight the importance of evaluating candidate 
analgesics across a broad range of experimental conditions. One potential explanation for the 
differential Ro 64-6198 antinociceptive results could be related to the experimental and 
pharmacological histories of the monkeys. For example, monkeys in the Ko, et al (2009) study 
had not been exposed to any opioid ligands for at least one month prior whereas monkeys in the 
present study had a more extensive and recent opioid ligand history (Cornelissen et al., 2018a; 
Cornelissen et al., 2018b). Thus, one interpretation could be that NOP agonists produce 
antinociception in opioid-naïve or minimally opioid-experienced primates. Although opioid 
ligand history did not impact the antinociceptive effects of mu-opioid ligands alone in the present 
study, the degree to which opioid ligand exposure may alter the antinociceptive effects of NOP 
agonists remains to be empirically determined.  
The opioid agonists nalbuphine, morphine, oxycodone, and methadone decreased rates of 
responding consistent with the extant literature (Banks et al., 2010b; Downs, 1979; Stevenson et 
al., 2003). The present results extend these findings to the KOR agonist nalfurafine. NAQ failed 
to significantly alter rates of responding in the present study. Previous studies have shown that 
NAQ decreases rates of food-maintained responding (Siemian et al., 2016) and to a lesser extent, 
electrical brain stimulation-maintained responding (Altarifi et al., 2015) in rats suggesting 
potential species difference in NAQ effectiveness to decrease operant behavior. Buprenorphine 
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also failed to significantly alter rates of responding and these results were consistent with 
previous buprenorphine results in male monkeys (Negus et al., 2002). Ro 64-6198 rate-
decreasing effects in the present study were consistent with previous Ro 64-6198 results in drug 
discrimination (Saccone et al., 2016) and extended previous findings by determining Ro 64-6198 
time course and sensitivity to SB-612111antagonism. Overall, the behavioral effects of the mu-
opioid ligands and nalfurafine alone in the present study provide an empirical foundation for 
examining interactions with Ro 64-6198.  
 
4.3 Interactions between Ro 64-6198 and mu-opioid or kappa-opioid agonists  
Ro 64-6198 significantly enhanced the antinociceptive effects of the mu-opioid ligands 
buprenorphine, nalbuphine, and methadone as well as nalfurafine. The present results were 
generally consistent with the direction, but not the magnitude, of previous mu-opioid and NOP 
agonist antinociceptive interactions with buprenorphine (Cremeans et al., 2012) and morphine 
(Hu et al., 2010; Ko and Naughton, 2009) in monkeys. NOP agonist enhancement of morphine 
antinociception has also been reported in mice (Reiss et al., 2008) and rats (Jin‐Hua et al., 1997). 
The present results extended upon these previous findings in three ways. First, NOP and mu-
opioid agonist antinociceptive interactions were not dependent upon mu-opioid agonist efficacy. 
Second, mu-opioid and NOP agonist antinociceptive interactions occurred under a narrow range 
of experimental conditions such as dose and pretreatment time that suggests limited clinical 
utility and effectiveness. Lastly, NOP agonist interactions were not selective for clinically 
effective mu-opioid agonists because Ro 64-6198 also enhanced nalfurafine-induced 
antinociception.  
In contrast to mu-opioid and NOP agonist antinociceptive interactions, Ro 64-6198 did 
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not significantly alter the rate-decreasing effects of any mu-opioid ligand examined. However, 
Ro 64-6198 significantly attenuated the rate-decreasing effects of cumulative 0.001mg/kg 
nalfurafine. These results suggest at least three main conclusions. First, Ro 64-6198 
enhancement of mu-opioid agonist antinociception was not due to generalized behavioral 
depression. However, one caveat is the Ro 64-6198 dose sufficient to enhance mu-opioid agonist 
antinociception was only 3-fold smaller than the dose that significantly decreased rates of 
responding. Thus, there may be a potential ceiling for the amount of NOP agonist in the 
NOP/mu-opioid drug mixture. Second, the present results are consistent with and extend 
previous NOP and mu-opioid agonist interactions to the mu-opioid agonist undesirable endpoint 
behavioral depression. Previous studies have reported that NOP agonists do not enhance the 
respiratory depressant, scratching-behavior, or reinforcing effects of mu-opioid agonists in 
monkeys (Cremeans et al., 2012; Ko et al., 2009; Podlesnik et al., 2011). Third, although Ro 64-
6198 attenuated the rate-decreasing effects of cumulative 0.001 mg/kg nalfurafine, nalfurafine 
produced maximal rate-depression at similar doses irrespective of pretreatment. Overall, despite 
mu-opioid and NOP agonist interactions displaying some degree of behavioral selectivity to 
produce antinociception vs. rate suppression, the magnitude of these interactions were small and 
not systematic across the various mu-opioid agonists.  
 
4.4 Comparison to mu-opioid Agonist and Other Drug Interactions  
Similar to mu-opioid and NOP agonist interactions, cannabinoid receptor agonists, delta-
opioid agonists, serotonin uptake inhibitors and serotonin receptor agonists have also produced a 
selective enhancement of mu-opioid agonist antinociception in rhesus monkeys (Banks et al., 
2010b; Gatch et al., 1998; Maguire and France, 2014; Negus et al., 2009; Stevenson et al., 2003). 
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For example, the serotonin uptake inhibitor clomipramine enhanced the antinociceptive effects of 
low efficacy mu-opioid agonists to a greater extent than high efficacy mu-opioid agonists (Banks 
et al., 2010b; Gatch et al., 1998). In contrast, cannabinoid agonists enhanced the antinociceptive 
effects of high efficacy mu-opioid agonists to a greater degree than low efficacy mu-opioid 
agonists (Maguire and France, 2014). Furthermore, delta agonist enhancement of mu-opioid 
agonist antinociception did not depend on mu-opioid agonist efficacy similar to the present NOP 
agonist effects (Negus et al., 2009; Stevenson et al., 2003). Overall, this literature supports 1) the 
inclusion of multiple dependent measures to assess behavioral selectivity in preclinical analgesia 
drug development and 2) the systematic evaluation of behavioral interactions with mu-opioid 
ligands that vary in efficacy.  
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Legends for Figures 
Fig 1: Time course of (−)-Ro 64-6198 and SB-612111 in assays of warm-water tail withdrawal 
at 50°C (panel A) and 54°C (panel B) and schedule-controlled responding (panel C). Abscissae: 
time in min after intramuscular Ro 64-6198 administration (log scale). Ordinates: percent 
maximal possible effect (panels A and B) or percent control rate (panel C). All points represent 
mean ± S.E.M. of 4 monkeys (except panel C where n=3). Asterisks denote significant (P<0.05) 
difference from vehicle and 0.32 mg/kg (−)-Ro 64-6198 + 0.32 mg/kg SB-612111. 
 
Fig 2: Antinociceptive effects (50°C) of NAQ, buprenorphine, nalbuphine, morphine, 
oxycodone, and methadone following vehicle or 0.1 mg/kg (−)-Ro 64-6198 pretreatment. 
Abscissae: cumulative intramuscular mu-opioid ligand dose in milligrams per kilogram (log 
scale). Ordinates: percent maximal possible effect (%MPE). All points represent mean ± S.E.M. 
of 4 monkeys (except NAQ and morphine which is n=3). Asterisks denote significant (P<0.05) 
difference from vehicle. 
 
Fig 3: Rate-decreasing effects of NAQ, buprenorphine, nalbuphine, morphine, oxycodone, and 
methadone following vehicle or 0.1 mg/kg (−)-Ro 64-6198 pretreatment. Abscissae: cumulative 
intramuscular mu-opioid ligand dose in milligrams per kilogram (log scale). Ordinates: percent 
control rate. All points represent mean ± S.E.M. of 3 monkeys. Asterisks points denote 
significant (P<0.05) difference from vehicle. 
 
Fig 4: Antinociceptive (50°C; Panel A) and rate-decreasing (Panel B) effects of nalfurafine 
following vehicle or 0.1 mg/kg (−)-Ro 64-6198 pretreatment. Abscissae: cumulative 
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intramuscular nalfurafine dose in milligrams per kilogram (log scale). Ordinates: percent 
maximal possible effect (%MPE; panel A) or percent control rate of responding (panel B). Points 
in panel A represent mean ± S.E.M. of 4 monkeys and panel B represent mean ± S.E.M. of 3 
monkeys. Asterisks denote significant (P<0.05) difference from vehicle. 
 
Fig 5: Antinociceptive effects (50°C) of nalbuphine following vehicle, (−)-Ro 64-6198, or SB 
612111 pretreatment. Panel A shows effects of different Ro 64-6198 doses. Panel B shows 
effects of different Ro 64-6198 pretreatment times. Panel C shows sensitivity to the NOP 
antagonist SB-612111. Abscissae: cumulative intramuscular nalbuphine dose in milligrams per 
kilogram (log scale). Ordinates: percent maximal possible effect (%MPE). All points represent 
mean ± S.E.M. of 3 monkeys. Asterisks denote significant (P<0.05) difference from vehicle. # 
denote significant difference (P<0.05) from Ro 64-6198 + SB-612111. 
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Table 1: Opioid ligand ED50 values (95% confidence limits; CL) following vehicle or 0.1 mg/kg 
(−)-Ro 64-6198 pretreatment in assays of thermal nociception (TW) and schedule-controlled 
responding (SCR) in male rhesus monkeys. All values represent group mean ED50 values of 3 
(SCR) or 4 (TW) monkeys unless otherwise denoted. a ED50 values are from three out of four 
monkeys.  
Opioid ligand 
TW (50°C)  
ED50 in mg/kg (95% CL) 
SCR  
ED50 in mg/kg (95% CL) 
Methadone  1.45 (1.01-1.89) 1.17 (0.66-1.68) 
+ Ro 64-6198 0.79 (0.52-1.06) 1.19 (0.63-1.74) 
Oxycodone  0.16 (0.02-0.30) 0.24 (0-1.14) 
+ Ro 64-6198 0.10 (0-0.45) 0.29 (0.13-0.45) 
Morphine (n=3) 3.27 (0-7.76) 0.74 (0-1.89) 
+ Ro 64-6198 (n=3) 1.55 (0.86-2.25) 2.17 (0-6.10) 
Nalbuphine  0.20 (0.04-0.36) 0.42 (0-1.19) 
+ Ro 64-6198 0.05 (0.05-0.07) 0.83 (0-2.88) 
Buprenorphine  0.28 (0-0.62)a NC 
+ Ro 64-6198 0.06 (0-0.30) NC 
NAQ  NC NC 
+ Ro 64-6198 NC NC 
Nalfurafine (n=3) NC 0.001 (0.001-0.002) 
+ Ro 64-6198 (n=3) 0.006 (0-0.012) 0.002 (0.001-0.014) 
NC: not calculable because no drug dose produced >50%MPE or decreased %Control rate below 
50% 
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Chapter 4: Expansion of the Furchgott equation for receptor theory by investigating the potential 
for fixed-proportion mixtures of competitive MOR antagonist and MOR agonist to manipulate 
antinociceptive efficacy in male rhesus monkeys. 
 
INTRODUCTION 
Pharmacodynamics is concerned with the affinity and efficacy of drugs at their receptor 
targets. Drug affinity can be precisely measured with ligand binding techniques, but drug 
efficacy to activate receptor signaling and produce downstream effects is a relative measure 
dependent in part on the signaling pathway(s) and downstream effects under consideration, and 
drug efficacies are typically described in relation to some standard high-efficacy ligand (Ruffolo, 
1982; Kenakin, 2012). Although efficacy is challenging to measure, it is clearly relevant in drug 
development. For example, mu-opioid receptor (MOR) ligands differ in their efficacy to activate 
MOR-coupled signal transduction processes and produce MOR-mediated effects such as 
analgesia and respiratory depression. Fentanyl has high MOR efficacy, and increasing fentanyl 
doses can produce both antinociception and lethal respiratory depression (Gerak et al., 1994; 
Banks et al., 2010a; Ding et al., 2016). At the other extreme of the efficacy continuum, 
naltrexone has little or no MOR efficacy, produces no agonist effects, and functions as a 
competitive reversible antagonist (Walker et al., 1994; Ko et al., 1998; Bowen et al., 
2002). Between these extremes are intermediate-efficacy MOR ligands like nalbuphine and 
buprenorphine that produce submaximal stimulation of MOR signaling and a subset of agonist 
effects that includes analgesia but only weak respiratory depression (Gerak et al., 1994; Pitts et 
al., 1998; Kishioka et al., 2000). Experiments to investigate the expression and consequences of 
ligand efficacy at MORs or other receptor targets can be useful both (a) to determine the efficacy 
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required to produce different effects of interest, and (b) to evaluate relative efficacy of new 
ligands as they are developed.    
One common approach to efficacy evaluations relies on the use of irreversible antagonists 
to evaluate the impact of reducing receptor number on expression of drug effects (Furchgott, 
1966; Kenakin, 1993; Bergman et al., 2000). Efficacy requirements for different effects can be 
estimated, because an irreversible antagonist will produce greater antagonism of effects with 
high vs. low efficacy requirements (Zernig et al., 1997). Relative efficacies of different drugs can 
be estimated, because an irreversible antagonist will produce greater antagonism of a low- vs. 
high-efficacy agonist (Zimmerman et al., 1987; Walker et al., 1998). However, studies with 
irreversible antagonists can be logistically challenging (e.g. due to the long duration of 
antagonist effects), and irreversible antagonists are not available for many receptors of interest. 
Decreases in receptor number can also be accomplished with genetic mutations, as in wild-type, 
heterozygous, and homozygous receptor knockout animals (Grim et al., 2016), but the degree of 
control over the magnitude of that decrease is limited. Receptor theory suggests an alternative, 
more precise, and more flexible strategy to investigate efficacy using mixtures of competitive 
agonists and antagonists. Figure 1A shows a theoretical dose-effect function for a high-efficacy 
agonist administered alone or in the presence of increasing fixed doses of an antagonist. The 
familiar result is an antagonist dose-dependent rightward shift in the agonist dose-effect curve 
(Ko et al., 1998; Negus et al., 2003). Figure 1B shows theoretical effects using a different 
experimental design, in which the agonist is administered in combination with fixed-proportional 
doses of the antagonist, such that increasing agonist doses are administered in combination with 
increasing antagonist doses. In this design, the antagonist is expected to produce proportion-
dependent downward shifts in the agonist dose-effect curve, and mixtures with decreasing 
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agonist-to-antagonist proportions have decreasing apparent efficacies to activate the receptor. 
This approach has two potential advantages relative to existing strategies. First, agonist-to-
antagonist proportion can be precisely manipulated to yield precise increments in efficacy. 
Second, this approach could be applied to any receptor system for which a competitive agonist 
and antagonist are available.   
 The goal of the present study was to test the utility of this approach using the competitive 
MOR agonist fentanyl and antagonist naltrexone (Negus et al., 1993; Emmerson et al., 1994; 
Walker et al., 1994; Emmerson et al., 1996).  Effects of these drugs administered alone and in 
fixed-proportion mixtures were determined in an assay of thermal nociception using two thermal 
stimulus intensities (50 and 54°C warm water) and compared to effects produced by six other 
MOR ligands shown previously to vary in their relative MOR efficacies in in vitro assays of 
agonist-stimulated GTPγS binding (Emmerson et al., 1996; Selley et al., 1998; Alt et al., 2001; 
Thompson et al., 2004; Yuan et al., 2015). We predicted that effects of fentanyl, naltrexone, and 
the mixtures would match predicted results in Figure 1B. Additionally, we predicted that 
maximal effects of fentanyl, naltrexone, and the mixtures could be used to generate efficacy-
effect scales for quantification of both (a) MOR efficacy requirements for antinociception at 50 
and 54°C, and (b) relative efficacies of the six MOR test ligands.       
 
METHODS 
Subjects 
Four adult male rhesus macaques (Macaca mulatta) of either Indian or Chinese origin 
and weighing between 10-14 kg served as subjects. All subjects had previous experimental 
histories that included exposure to opioid ligands, monoaminergic transporter ligands, and N-
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methyl D-aspartate antagonists. Monkeys were fed a diet of laboratory biscuits (#5049, Purina, 
Framingham, MA) supplemented with fresh fruits, vegetables, and nuts to maintain healthy, 
stable body weights. Monkeys were individually housed in a temperature and humidity 
controlled room that was maintained on a 12-h light/12-h dark cycle (lights on from 6:00 AM 
until 6:00 PM). Water was available ad libitum in the housing chamber. The facility was licensed 
by the United States Department of Agriculture and accredited by AAALAC International. Both 
research and enrichment protocols were approved by the Institutional Animal Care and Use 
Committee and in accordance with the 2011 Guide for the Care and Use of Laboratory Animals. 
Environmental enrichment included: music, movies, puzzle feeders, and chew toys. Furthermore, 
monkeys were afforded opportunities to interact socially using olfactory and auditory cues; 
mirrors provided additional opportunities for visual interaction. 
 
Assay of thermal nociception 
 Monkeys were trained to sit comfortably in an acrylic restraint chair using the pole-and-
collar technique such that their tails hung freely. The subject’s tail was shaved 10-12 cm from 
the distal end weekly and immersed in a thermal container of warm water. If the subject did not 
remove its tail by 20 s, the tail was removed by the experimenter, and a latency of 20 s was 
assigned. A stopwatch was utilized to record tail-withdrawal latencies. During each 15-min 
cycle, tail-withdrawal latencies were recorded from water warmed to 38°C, 50°C, and 54°C and 
the order of warmed water presentations varied between successive cycles. Baseline tail-
withdrawal latencies at all three thermal intensities were determined in each daily test session 
before drug administration. Test sessions continued only if tail-withdrawal latencies from 38°C 
water did not occur before the 20-s cutoff. This criterion was met in every monkey during every 
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test session. Cumulative dose test sessions consisted of four to six 15-minute cycles composed of 
a 10-minute drug pretreatment phase and a 5-min testing phase. Drugs were administered 
intramuscularly (IM) at the start of each 15-min cycle, and each drug dose increase the total 
cumulative dose by one-fourth or one-half log units. Tail-withdrawal latencies were 
redetermined during the 5-min testing phase as described above.  
 Initially, dose-effect functions were determined for fentanyl (0.001-0.056 mg/kg, IM) and 
naltrexone (0.032-1 mg/kg, IM) alone and each dose-effect function was determined twice. 
Subsequently, three fixed-proportion fentanyl and naltrexone mixtures were examined and each 
cumulative dose-effect function was determined once. The proportions of each drug in the three 
test mixtures were based on the published affinities (Kd) of fentanyl (1.48 nM) and naltrexone 
(0.11 nM) at the mu-opioid receptor in rhesus monkey brain (Emmerson et al., 1994). 
Specifically, the fixed-proportion of fentanyl to naltrexone for one mixture, denoted as the 1:1 
mixture, was set to the proportion of their Kd values (1.48:0.11 = 1:0.074). Relative to the 1:1 
mixture, the 3:1 fentanyl/naltrexone mixture had a three-fold higher proportion of fentanyl to 
naltrexone (1:0.025), and the 1:3 fentanyl/naltrexone mixture had a three-fold lower proportion 
of fentanyl to naltrexone (1:0.22). Mixtures were tested up to doses that produced maximal 
antinociception, undesirable physiological effects such as respiratory depression, or antagonized 
fentanyl effects in other studies. Experiments were generally conducted twice per week, usually 
on Tuesdays and Fridays, with at least three days between test days.  
Following these initial fentanyl/naltrexone fixed-proportion experiments, three additional 
studies were conducted. First, for comparison to effects of the fentanyl/naltrexone mixtures, 
cumulative dose-effect functions were determined for a series of six other MOR ligands that vary 
from low to high in their efficacy at mu receptors as determined by in vitro assays of agonist-
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stimuluated GTPγS binding (Emmerson et al., 1996; Selley et al., 1998; Alt et al., 2001; 
Thompson et al., 2004; Yuan et al., 2015): 17-cyclopropylmethyl-3,14β-dihyroxy-4,5α-epoxy-
6α-[(3´-isoquinolyl)acetamindo]morphinan (NAQ) (0.1-10 mg/kg, IM),  buprenorphine (0.032-
3.2 mg/kg, IM), nalbuphine (0.032-3.2 mg/kg, IM), morphine (0.1-10 mg/kg, IM), oxycodone 
(0.01-1 mg/kg, IM), and methadone (0.1-5.6 mg/kg, IM). Each dose-effect function was 
determined once. Drugs were tested up to doses that produced maximal antinociception, 
undesirable physiological effects such as respiratory depression, or antagonized fentanyl effects 
in other studies. These experiments were generally conducted twice per week, except for studies 
with buprenorphine, nalbuphine, and morphine, which were separated by at least 7 days to allow 
dissipation of long-acting drug effects and/or to minimize potential effects of antinociceptive 
tolerance. Second, receptor theory predicts that pretreatment with a low-efficacy agonist should 
attenuate the potency, but not efficacy, of a higher efficacy agonist and thus shift the higher 
efficacy agonist dose-effect function to the right. To test this hypothesis, fixed-dose pretreatment 
experiments were conducted with naltrexone (0.0032-0.032 mg/kg, IM), NAQ (10 mg/kg, IM), 
or 1:0.22 fentanyl/naltrexone mixture (0.032 mg/kg fentanyl + 0.007 mg/kg naltrexone, IM) to 
cumulative fentanyl (0.001-1 mg/kg, IM), and each experiment was singly determined. 
Naltrexone, NAQ, and the fentanyl/naltrexone mixture were administered 15 min before the first 
fentanyl dose. Lastly, drug interactions can be influenced not only by the relative drug doses in a 
mixture, but also by their relative time courses. Accordingly, the time course of 0.056 mg/kg 
fentanyl was determined when combined with naltrexone as a 1:0.074 fixed-proportion mixture 
for simultaneous administration of both drugs, and when the equivalent naltrexone dose (0.0041 
mg/kg) in the 1:0.074 fentanyl/naltrexone mixture was administered 3 min before or 3 min after 
0.056 mg/kg fentanyl alone. Tail-withdrawal latencies were redetermined 10, 30, and 100 min 
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after fentanyl administration unless emergence of respiratory depression required rescue with 
additional naltrexone treatments. These experiments were generally conducted twice per week. 
 
Data Analysis 
Drug effects were expressed as %Maximum Possible Effect (%MPE) using the following 
equation: 
%𝑀𝑃𝐸 =  (𝑇𝑒𝑠𝑡 𝑙𝑎𝑡𝑒𝑛𝑐𝑦 − 𝐵𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝑙𝑎𝑡𝑒𝑛𝑐𝑦) (20− 𝐵𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝑙𝑎𝑡𝑒𝑛𝑐𝑦) ∗ 100 
where test latency was the tail-withdrawal latency from either 50°C or 54°C water obtained after 
drug administration, and baseline latency was the latency from either 50°C or 54°C water 
obtained before drug administration. Maximum antinociceptive effects were also determined for 
each drug or mixture at the group mean and individual level for each thermal stimulus intensity. 
Maximum effect was defined as the highest effect produced by any dose. Group mean maximum 
effects were compared using a one-way repeated-measures analysis of variance, and a Tukey 
post-hoc test was conducted following a significant main effect. In addition, maximum effect 
values were used in the analysis described in the next paragraph. 
 Theoretically, fentanyl/naltrexone mixtures should be useful to generate precise 
increments in efficacy that can be used 1) to generate mixtures with efficacies not available in 
existing single molecules, 2) to calibrate efficacy requirements for drug effects in different 
procedures, and 3) to infer efficacies of other drugs tested in those procedures. For example, if 
the relative efficacies of naltrexone and fentanyl are set arbitrarily at 0 and 1, respectively, then 
mixtures of 1:3, 1:1 and 3:1 fentanyl/naltrexone (after correcting for ligand affinity) will have 
relative efficacies along this continuum of 0.25, 0.5, and 0.75 respectively (i.e. relative efficacy = 
fractional contribution of fentanyl to the total drug in the mixture). The efficacy requirement of a 
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given procedure can then quantified by (a) testing effects of fentanyl and naltrexone alone and of 
all three mixtures, (b) generating efficacy-effect functions to relate maximum effects of each 
drug and mixture to the fentanyl proportion and associated relative efficacy, and (c) using 
nonlinear regression to determine the EP50 value, defined as the “effective proportion” of 
fentanyl to produce a maximum effect equal to 50% MPE in that procedure. EP50 values can then 
be compared across procedures. Additionally, once the efficacy-effect relationships are 
established, efficacy of a test drug can then be estimated as the fentanyl proportion that produces 
maximum effects equivalent to that of the test drug. To evaluate the utility of this approach, 
efficacy-effect curves were generated using nonlinear regression (GraphPad Prism, La Jolla, CA) 
to fit maximum effects data for fentanyl alone, naltrexone alone, and each mixture at each 
temperature using the equation: 
𝐸𝑓𝑓𝑒𝑐𝑡
= 100 
× (𝑓𝑒𝑛𝑡𝑎𝑛𝑦𝑙 𝑝𝑟𝑜𝑝𝑜𝑟𝑡𝑖𝑜𝑛
!"## !"#$%)
𝐸𝑃50!"## !"#$% +  (𝑓𝑒𝑛𝑡𝑎𝑛𝑦𝑙 𝑝𝑟𝑜𝑝𝑜𝑟𝑡𝑖𝑜𝑛!"## !"#$%  ))
 
where fentanyl proportion was the fractional contribution of fentanyl to the total drug in the 
mixture, and EP50 was the fentanyl proportion that produced a maximum effect equivalent to 
50% maximum possible effect. Relative efficacies of test compounds were then estimated for 
each individual monkey by comparing maximum effects of each drug at each temperature with 
the group mean efficacy-effect curves. Specifically, relative efficacy was defined as the fentanyl 
proportion at which maximum effects of the test drug deviated least from the efficacy-effect 
functions. Deviation was quantified as the sum of the differences between test drug maximum 
effect and efficacy-effect curve at both 50 and 54°C, and the fentanyl proportion was identified 
at which deviation was smallest. Individual test drug values were then averaged to yield group 
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mean values and these data were analyzed using a one-way repeated measures analysis of 
variance. In the presence of a significant main effect, comparisons between test drug maximum 
effects were made using the Tukey’s test.  
 For pretreatment and time course studies, two-way repeated-measures analysis of 
variance was performed with experimental manipulation (e.g. pretreatment) and fentanyl dose or 
time after fentanyl administration as the main independent variables. Following a significant 
interaction, a Holm-Sidak post-hoc test was performed, and the criterion for significance was 
p<0.05. Naltrexone pA2 values were determined as described previously (Bowen et al., 2002).  
 
Drugs 
 Fentanyl HCl, (−)-naltrexone HCl, morphine sulfate, and (−)-oxycodone HCl were 
supplied by the National Institute on Drug Abuse Drug Supply Program (Bethesda, MD). (−)-
Nalbuphine HCl was provided by Dr. Kenner Rice (Drug Design and Synthesis Section, National 
Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, Bethesda, 
MD). (±)-Methadone HCl and (±)-buprenorphine HCl were purchased from Spectrum Chemicals 
(Gardena, CA). NAQ HCl was synthesized and provided by Dr. Yan Zhang (Li et al., 2009). 
Fentanyl, naltrexone, buprenorphine, nalbuphine, oxycodone, morphine, methadone, and all 
mixtures were dissolved in sterile water. NAQ was dissolved in 50% dimethyl sulfoxide (Sigma-
Aldrich, St. Louis, MO) and 50% sterile water. All drug doses were expressed as the salt forms 
listed above, and administered intramuscularly in the thigh. 
 
RESULTS 
Fentanyl-Naltrexone fixed-proportion mixtures 
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 Across all baseline sessions before drug administration, monkeys always left their tail in 
38°C water for 20 s, and the mean tail withdrawal latencies at 50°C and 54°C were 1.1 ± 0.5 s 
and 0.7 ± 0.1 s, respectively. Figure 2 left panels show the antinociceptive effects of fentanyl 
alone and following fixed naltrexone dose (0.0032-0.032 mg/kg, IM) pretreatments at 50°C (top) 
and 54°C (bottom). Fentanyl alone produced dose-dependent and full (≥90%MPE) 
antinociception at both temperatures in all monkeys. Increasing naltrexone dose pretreatments 
produced parallel rightward shifts in the fentanyl dose-effect function at both temperatures. 
Mean fentanyl ED50 values are shown in Table 3, and the naltrexone pA2 values (95% 
confidence limits) were 8.58 (8.35, 8.82) and 8.50 (7.96, 8.52) for 50°C and 54°C, respectively. 
Figure 2 right panels show the antinociceptive effects of fentanyl alone, naltrexone alone, and the 
three fentanyl/naltrexone mixtures at 50°C (top) and 54°C (bottom). Maximum effect values 
from mean dose-effect curves are shown in Table 1, and maximum effect values in individual 
monkeys are shown in Table 2. As in the left panels, fentanyl alone produced dose-dependent 
antinociception, whereas naltrexone alone was ineffective at both temperatures (<5% MPE). 
Fentanyl/naltrexone mixtures produced a naltrexone proportion-dependent decrease in maximum 
effects. Fentanyl alone and the 1:0.025 fentanyl/naltrexone mixture produced maximum effects 
that were significantly different from both naltrexone alone and the 1:0.22 fentanyl/naltrexone 
mixture at both 50°C and 54°C (50°C: F1.5,4.4=16.0, p=0.0111; 54°C: F1.9,5.7=31.3, p=0.0009). 
 
 
MOR ligands 
 Figure 3 shows the antinociceptive effects of the MOR ligands NAQ, nalbuphine, 
buprenorphine, oxycodone, morphine, and methadone at both 50°C (top) and 54°C (bottom). 
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Maximum effects values from mean dose-effect curves are shown in Table 1, and maximum 
effect values in individual monkeys are shown in Table 2. All drugs except NAQ produced 
maximum or near maximum antinociceptive effects at 50°C, and the rank of order of maximum 
effects at 54°C (from lowest to highest) was NAQ, buprenorphine, nalbuphine, morphine, 
oxycodone and methadone. In general, the sensitivity of individual monkeys to declining 
efficacy of fentanyl/naltrexone mixtures paralleled sensitivity to declining efficacy of test 
compounds. For example, the 1:0.22 fentanyl/naltrexone mixture produced the greatest 
antinociceptive effect at 54°C (44.2%MPE) in M1478, and this monkey also displayed the 
greatest or close to the greatest maximum individual antinociceptive effect at 54°C following 
nalbuphine, buprenorphine, or NAQ administration. In contrast, the 1:0.074 fentanyl/naltrexone 
mixture produced the least antinociceptive effect at 54°C in M1503, and this monkey also 
showed the weakest or close to the weakest individual antinociceptive effects at 54°C following 
nalbuphine, buprenorphine, or NAQ administration. 
 
Efficacy estimates of MOR  ligands relative to fentanyl and naltrexone 
 Figure 4A shows efficacy-effect curves that relate %MPEmax effects of fentanyl, 
naltrexone, and each mixture at 50 and 54°C to the proportion of fentanyl in the mixture from 0 
(naltrexone alone) to 1 (fentanyl alone). Comparison of the nonlinear fits for the two different 
temperatures using the extra sum-of-squares F-test demonstrated that each temperature data set 
was best fit by different nonlinear functions (F2,6=7.3, p=0.0249). For 50°C, the hill slope was 
4.26, EP50 value (95% confidence limits) was 0.39 (0.34, 0.46), and R2 was 0.99. For 54°C, the 
hill slope was 6.66, EP50 value was 0.53 (0.41, 0.61), and R2 was 0.98. The 95% confidence 
limits for the EP50 values at 50 and 54°C overlapped. Figure 4B shows the best fit for the 
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maximum effect of each test drug to the efficacy-effect curves defined by the naltrexone-to-
fentanyl continuum. Using this analysis, the efficacy of each compound relative to the 
naltrexone-to-fentanyl continuum was determined and results reported in Table 4. Comparison of 
maximum effects demonstrated that fentanyl and methadone both produced significantly higher 
maximum effects compared to buprenorphine, NAQ, and naltrexone (F2.3, 6.8=23.3, p=0.0008). In 
addition, buprenorphine also produced significantly higher maximum effects compared to NAQ.  
 
Effects of NAQ or fentanyl/naltrexone (1:0.22) pretreatment 
 Figure 5 shows cumulative fentanyl dose-effect functions alone or following a 15-min 
pretreatment with the low-efficacy MOR ligand NAQ (10 mg/kg; left panels) or the low-efficacy 
1:0.22 fentanyl/naltrexone mixture (0.032 mg/kg; right panels) at both 50°C (top) and 54°C 
(bottom) thermal intensities, and fentanyl ED50 values are shown in Table 3. Consistent with the 
results described in Figure 2, fentanyl alone produced dose-dependent antinociception at both 
thermal intensities. NAQ pretreatment produced a significant (~9-fold) increase in the fentanyl 
ED50 value at 54°C (Table 3) and significantly attenuated the antinociceptive effects of 
cumulative 0.032 mg/kg fentanyl (fentanyl dose: F2,6=566.3, p<0.0001; NAQ: F1,3=176, 
p=0.0009; interaction: F2,6=367.1, p<0.0001). Conversely, pretreatment with 0.032 mg/kg 1:0.22  
fentanyl/naltrexone did not significantly increase in the fentanyl ED50 value at 54°C (Table 3), 
although it did significantly decrease the antinociceptive effects of cumulative 0.032 mg/kg 
fentanyl at 54°C (fentanyl dose: F2,6=24.4, p=0.0013; interaction: F2,6=16.1, p=0.0038).  
 
Time course as a factor in drug-interaction studies 
 Figure 6 shows the time course of antinociception produced at 50 and 54°C by 0.056 
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mg/kg fentanyl administered in combination with 0.0041 mg/kg naltrexone. When these two 
doses were administered simultaneously (i.e. 0.056 mg/kg of the 1:0.074 fentanyl/naltrexone 
mixture), submaximal antinociceptive effects were observed at both 50 and 54°C, and these 
effects dissipated after 30-100 min.  The effects of this bolus mixture after 10 min were similar 
to the effects observed when the same dose of this mixture was tested as part of the cumulative 
dose-effect curve (from Figure 2). Additionally, the effects of this bolus mixture dose were 
similar to effects observed with the fentanyl dose was administered three min after the naltrexone 
dose. However, when fentanyl was administered three min before naltrexone, the experiment had 
to be terminated because of severe sedation and respiratory depression in two monkeys that 
required additional naltrexone administration.   
 
Discussion 
The primary aim of the present study was to evaluate the degree to which fixed-
proportion mixtures of fentanyl and naltrexone would produce effects predicted by receptor 
theory for mixtures of a competitive reversible agonist and antagonist targeting a common 
receptor. A secondary aim was to evaluate the utility of results with fentanyl/naltrexone mixtures 
for establishing an efficacy-effect scale that could be used to quantify (a) efficacy requirements 
for different drug effects, and (b) relative efficacies of different MOR ligands. There were three 
main findings. First, as predicted by receptor theory, the addition of naltrexone to fentanyl 
produced a naltrexone proportion-dependent decrease in the maximal antinociceptive effects of 
fentanyl/naltrexone mixtures. Second, the proportion of fentanyl in the mixtures served as a 
metric for efficacy of the mixtures, and this scale provided a strategy for quantifying efficacy 
requirements for different drug effects (i.e. antinociception at 50°C vs. 54°C) and relative in vivo 
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efficacies of different MOR ligands. Lastly, the results reported here also provide insight into 
factors that can limit utility of this approach. Overall, these results support the potential use of 
agonist/antgonist mixtures as tools in basic research, while also suggesting factors that may 
influence the usefulness of this approach.  
Fentanyl alone produced dose- and thermal intensity-dependent antinociception in rhesus 
monkeys, whereas naltrexone alone produced <10%MPE up to the largest doses tested. These 
results were consistent with a large body of literature demonstrating the antinociceptive effects 
of fentanyl in humans (Finch and DeKornfeld, 1967), nonhuman primates (Nussmeier et al., 
1991; Gatch et al., 1995; Maguire and France, 2014) and rodents (Millan, 1989; Walker et al., 
1994; Minami et al., 2009). Because naltrexone failed to produce significant antinociception, one 
method to determine whether a behaviorally active dose range was administered would be to 
give naltrexone as a pretreatment to cumulative fentanyl. In this experiment, receptor theory 
would predict that increasing naltrexone fixed-dose pretreatments would produce parallel 
rightward shifts in the fentanyl dose-effect function. The present results were consistent with this 
hypothesis, and the naltrexone pA2 values reported in this study were consistent with previous 
naltrexone studies in monkeys (Rowlett et al., 2000; Bowen et al., 2002; Gerak and France, 
2007). Overall, these results provide an empirical foundation to interpret the antinociceptive 
effects of fixed-proportion fentanyl and naltrexone mixtures.  
Receptor theory predicts that fixed-proportion mixtures of a competitive reversible 
agonist and antagonist should produce maximal effects that decline as the proportion of agonist 
in the mixture declines. Results support this prediction. Specifically, the MOR agonist fentanyl 
produced dose-dependent antinociception at both 50 and 54°C, and mixtures of fentanyl with the 
MOR antagonist naltrexone produced decreasing maximal antinociceptive effects as the 
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proportion of fentanyl in the mixture decreased. The declining maximal effects of 
fentanyl/naltrexone mixtures with declining fentanyl proportions resembles the declining 
maximal effects of mu agonists produced by pretreatments with irreversible antagonists (Zernig 
et al., 1994; Walker and Young, 2002). As such, fixed-proportion mixtures with competitive 
antagonists may serve as an alternative to use of irreversible antagonists for research on the role 
of efficacy as a determinant of drug effects. This approach may be especially useful in research 
on systems for which competitive antagonists are available, but irreversible antagonists are 
not.       
Because the agonist/antagonist proportion determined the apparent efficacy of a mixture, 
this proportion could be used as a quantitative measure of in vivo efficacy. In the present study, 
this metric was applied in two ways. First, we evaluated the efficacy requirements for 
antinociception at 50 and 54°C by comparing the fentanyl proportion required to produce a 
maximal effect of 50% MPE at each temperature. Although the 95% confidence limits for these 
values overlapped, the higher mean value at 54°C agrees with other data to suggest that efficacy 
requirements for antinociception are higher at 54°C than 50°C (Walker et al., 1993; Banks et al., 
2010b; Maguire and France, 2014). Additionally, although this study compared efficacy 
requirements of similar endpoints (i.e. antinociception at two different stimulus intensities in 
rhesus monkeys), it is theoretically possible to apply this approach across multiple endpoints that 
could include not only other behavioral and physiological endpoints in rhesus monkeys, but also 
endpoints in other species or in in vitro assays. For example, two undesirable effects of MOR 
agonists that limit their clinical utility are respiratory depression and abuse liability, and 
fentanyl/naltrexone mixtures could be used to quantify the efficacy requirement for each of these 
or any other MOR agonist effect of interest. These experiments would also provide empirical 
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data on the utility of agonist/antagonist mixtures to assess the efficacy requirements of different 
experimental endpoints. 
 A second implication of the present study was that fentanyl/naltrexone mixtures could be 
used to stratify MOR ligands based on their in vivo antinociceptive efficacy in rhesus monkeys. 
In the present study, NAQ produced < 10%MPE and these results are consistent with and extend 
previous findings in mice (Zhang et al., 2014; Yuan et al., 2015) and rats (Siemian et al., 2016). 
Buprenorphine (Walker et al., 1995; Maguire and France, 2014), nalbuphine (Walker et al., 
1993; France and Gerak, 1994; Banks et al., 2010b), morphine (Bowen et al., 2002), oxycodone, 
and methadone (Stevenson et al., 2003; Banks et al., 2010b) produced dose- and thermal 
intensity-dependent antinociception in the present study, and these results were generally 
consistent with the extant literature examining MOR agonists in a warm-water tail-withdrawal 
procedure in monkeys. With one major exception (see below regarding nalbuphine), the order of 
MOR efficacies for these drugs as ranked here agrees with the order of efficacies as determined 
by in vitro approaches such as agonist-stimulated GTPγS binding (Selley et al., 1998; Alt et al., 
2001; Yuan et al., 2015). Specifically, both approaches yield a rank order of lowest-to-highest 
efficacy of naltrexone < NAQ < buprenorphine < morphine < oxycodone < fentanyl < 
methadone. By comparing effects of these mu agonists to effects of fentanyl/naltrexone mixtures, 
it was possible not only to rank order drug efficacies, but also to provide a quantitative measure 
of those relative efficacies, expressed as fentanyl proportion.  
 Results with nalbuphine in the present study did not agree with previous in vitro results 
using agonist-stimulated GTPγS binding with either mouse MOR (Selley et al., 1998) or rat 
MOR (Alt et al., 2001). The basis for this difference between published GTPγS results and 
antinociceptive efficacy in rhesus monkeys remains to be empirically determined. Although there 
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are no published GTPγS results with any MOR ligand using monkey MOR, two lines of 
evidence support the conclusion that nalbuphine functions as a higher efficacy MOR ligand than 
buprenorphine in rhesus monkeys. First, in HEK cells expressing MOR and examining inhibition 
of forskolin-stimulated cAMP accumulation, nalbuphine produced similar efficacy to morphine 
(Gharagozlou et al., 2003). Second, the present nalbuphine results demonstrating greater 
antinociceptive effects of nalbuphine compared to buprenorphine are generally consistent with 
previously published studies in nonhuman primates (Walker et al., 1993; Walker et al., 1995; 
Maguire and France, 2014). In addition to these antinociceptive studies, nalbuphine also shows 
higher efficacy than buprenorphine in an assay of schedule-controlled responding. For example, 
nalbuphine produced dose-dependent and near complete suppression of operant responding 
(Stevenson et al., 2003; Banks et al., 2010b), whereas buprenorphine decreased operant 
responding to approximately 65% of control (Negus et al., 2002). Overall, the present results 
highlight potential species differences in MOR ligand efficacy and support the utility of 
nonhuman primates in preclinical pharmacology research.  
 Although the present results support the concept that agonist/antagonist mixtures can be 
used manipulate apparent in vivo efficacy, these results also revealed factors that can influence 
the precision of this approach. Two particular limitations will be mentioned here. First, the 
efficacies of the constituent drugs in a mixture define the upper and lower boundaries of efficacy 
that can be assessed. For example, in the present study, fentanyl served as the agonist, and 
studies of in vitro agonist-stimulated GTPγS binding suggest that some MOR ligands (e.g. 
methadone) may have higher efficacy than fentanyl (Selley et al., 1998; Alt et al., 
2001). Because fentanyl defines the upper boundary of efficacy than can be achieved with 
fentanyl/naltrexone mixtures, these mixtures would not be useful for scaling effects of drugs like 
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methadone that may have higher efficacy than fentanyl. Similarly, these mixtures would not be 
useful for scaling effects of drugs that have lower efficacy than naltrexone.  
Second, although agonist/antagonist proportions can be precisely controlled in a 
mixture, the pharmacokinetics and associated time courses of the constituent drugs play a key 
role in determining the proportional drug concentrations at receptor targets after a in vivo drug 
administration. For example, in the present study, cumulative administration of the 1:0.074 
fentanyl/naltrexone mixture could be safely studied at doses up to 0.32 mg/kg.  However, bolus 
administration of this mixture at dose of 0.1 mg/kg fentanyl + 0.0074 mg/kg naltrexone could not 
be studied due to the onset of severe sedation and respiratory depression in at least one 
monkey. This suggests that, after bolus administration, fentanyl distributes more quickly than 
naltrexone to receptors that mediate sedation and respiratory depression. This difference may be 
mitigated during cumulative dosing by sustained effects of naltrexone doses administered early 
in the dosing regimen. Additionally, the impact of these pharmacokinetic issues may be 
influenced by both the agonist/antagonist proportion and overall mixture dose. For example, in 
the present study, both cumulative and bolus administration of 0.056 mg/kg 1:0.074 
fentanyl/naltrexone produced similar effects. However, administration of fentanyl just three min 
before naltrexone resulted in severe sedation and respiratory depression. Overall, these results 
highlight time course of drug effects as a key consideration in the deployment of competitive 
agonist/antagonist mixtures for both basic research or clinical studies.  
As a final note, the present results with fentanyl/naltrexone mixtures can be compared to 
development of opioid formulations that include a MOR agonist in combination with the 
competitive reversible antagonist naloxone (e.g. fixed-proportion formulations of oxycodone + 
naloxone or buprenorphine + naloxone) (Mendelson and Jones, 2003; Chen et al., 2014; Fanelli 
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and Fanelli, 2015; O'Brien, 2015). Consumption of these products by intended enteral routes of 
administration results in naloxone distribution to the gastrointenstinal tract (which may reduce 
constipating effects of the agonist), but limited distribution to the central nervous system due to 
extensive first-pass metabolism by the liver (resulting in limited interference with centrally 
mediated agonist effects). However, parenteral administration bypasses first-pass metabolism, 
resulting in greater naloxone distribution to the central nervous system and potential blockade of 
centrally mediated agonist effects and/or precipitation of withdrawal in opioid-dependent 
subjects. As a result of these characteristics, naloxone combination products are thought to have 
fewer gastrointestinal side effects and lower abuse liability than the agonists alone. The 
experimental design deployed in the present study could be used to test this hypothesis, with the 
caveat that naloxone’s relatively short duration of action may hamper naloxone’s utility for this 
type of research. For example, naloxone should be more potent to produce proportion-dependent 
downward shifts in agonist dose-effect curves for gastrointenstinal than centrally-mediated 
effects after enteral but not parenteral administration. The present study also suggests how the 
general concept of agonist+antagonist mixtures can be expanded beyond naloxone-containing 
combination products to include other antagonists such as naltrexone, or agonist+antagonist 
mixtures targeting other receptors, yielding mixtures with other pharmacological profiles.  
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Figure Legends 
Figure 1: Theoretical curves simulated from the Furchgott equation for receptor theory (Ruffolo, 1982). 
Left panel shows rightward shifts in a competitive reversible agonist dose-effect function after pretreatment 
with increasing fixed doses of a competitive reversible antagonist. Right panel shows downward shifts in a 
competitive reversible agonist dose-effect function when agonist and antagonist are co-administered in 
fixed-proportion mixtures. Equations and definition of terms are shown below the panels. For this 
simulation, agonist dose A and antagonist dose B vary in KD units (i.e. at a dose of 1, dose = KD); Rt was set 
arbitrarily at 100, and all other variables were set arbitrarily at 1. Note that in the left panel, antagonist dose 
is a fixed dose B that remains constant across a range of agonist doses. For the right panel, antagonist dose 
is a fixed proportion p of the agonist dose A, such that B=pA and increases in agonist dose are accompanied 
by increases in antagonist dose.     
 
Figure 2: Effects of fixed-dose naltrexone pretreatments to fentanyl and fixed-proportion 
fentanyl/naltrexone mixtures in an assay of thermal nociception in male rhesus monkeys. Left panels show 
effects of fentanyl alone and after increasing naltrexone doses administered as a 15-min pretreatment to 
fentanyl at 50°C (top) and 54°C (bottom) thermal intensities. Right panels show effects of fentanyl alone, 
naltrexone alone, and three fentanyl/naltrexone mixtures at 50°C (top) and 54°C (bottom). Abscissae: 
cumulative intramuscular fentanyl dose (left panels) or cumulative drug dose (right panels)  in mg/kg.  Note 
that for data with fentanyl/naltrexone mixtures in the right panels, the abscissa shows the fentanyl dose in 
the mixture, and the naltrexone dose = fentanyl dose x naltrexone proportion. Ordinates: % maximum 
possible effect (%MPE). All points represent mean ± SEM of 4 monkeys. 
 
Figure 3: Effects of six different MOR ligands in an assay of thermal nociception in male rhesus monkeys. 
Top panel shows effects of NAQ, nalbuphine, buprenorphine, morphine oxycodone, and methadone at 
50°C, and bottom panel shows effects at 54°C. Abscissae: cumulative intramuscular drug dose (mg/kg). 
Ordinates: % maximum possible effect (%MPE). All points represent mean ± SEM of 4 monkeys. 
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Figure 4: Top panel (A) shows maximum antinociceptive effect at 50°C (triangles) and 54°C (squares) as a 
function of the fentanyl proportion in the fentanyl/naltrexone mixture in male rhesus monkeys. Bottom 
panel (B) shows empirically determined maximum antinociceptive effects of NAQ, buprenorphine, 
nalbuphine, morphine, oxycodone, and methadone. Results were fit to the model generated from the top 
panel, and relative efficacy of each ligand was estimated as the fentanyl proportion to produce maximum 
effects at 50 and 54°C most like the test ligand. Abscissae: Efficacy expressed as Proportion Fentanyl. “0” 
denotes naltrexone alone, “1” denotes fentanyl alone, and the efficacy of each mixture (Emix) was 
calculated as the fractional contribution of fentanyl to the mixture as described in Methods. Ordinates: 
Maximum Effect. All points represent mean ± SEM of 4 monkeys. 
 
Figure 5: Effects of cumulative fentanyl (0.001-0.32 mg/kg, IM) administered either alone or following a 
15-min pretreatment with either 10 mg/kg NAQ (left panels) or 0.032 mg/kg fentanyl/naltrexone (1:0.22) 
(right panels) in rhesus monkeys. Abscissae: cumulative intramuscular fentanyl dose (mg/kg). Ordinates: % 
maximum possible effect (%MPE). All points represent mean ± SEM of 4 monkeys. Filled points denote 
statistical significance (p<0.05) compared to fentanyl alone. 
 
Figure 6: Time course of antinociceptive effects of 0.056 mg/kg fentanyl in combination with 0.0041 
mg/kg naltrexone administered simultaneously as a bolus dose of the 1:0.074 fentanyl/naltrexone mixture or 
with the naltrexone dose administered as a 3-min pretreatment to the fentanyl dose in rhesus monkeys. 
Antinociceptive effects of cumulative 0.056 mg/kg 1:0.074 fentanyl/naltrexone from Figure 2 are also 
plotted for comparison. Abscissae: fentanyl dose (mg/kg). Ordinate: % maximal possible effect (%MPE). 
Each point represents mean ± SEM of 4 monkeys. 
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Table 1: Group mean %MPEmax values and (±SEM) for each fentanyl/naltrexone combination or 
test drug administered in an assay of thermal nociception at 50°C and 54°C in rhesus monkeys 
(n=4). 
 
Drug or Drug Mixture 
%MPEmax  
(SEM) 
50°C 54°C 
Fentanyl 100 (0) ∗,† 96.4 (2.8) 
∗
,† 
1:0.025 
Fentanyl/Naltrexone 
100 (0) ∗,† 95.3 (4.7) 
∗
,† 
1:0.074 
Fentanyl/Naltrexone 
70.8 
(24.2) 
40.4 
(14.9) 
1:0.22 
Fentanyl/Naltrexone 
14.5 (9.5) 12.9 
(10.7) 
(−)-Naltrexone -1.8 (5.6) 0.9 (0.4) 
   
(±)-Methadone 100 (0) 100 (0) 
(−)-Oxycodone 100 (0) 89.5 (6.7) 
(−)-Morphine 100 (0) 78.1 (9.9) 
(−)-Nalbuphine 100 (0) 64.1 
(14.5) 
(±)-Buprenorphine 93.3 (6.7) 14.0 (6.0) 
NAQ 8.9 (6.9) 5.1 (3.7) 
∗ Significantly	different	from	Naltrexone	(p	<	0.05)	
† Significantly different from 1:0.025 Fentanyl/Naltrexone mixture (p < 0.05) 
 
Table 2: Individual %MPEmax values for each fentanyl/naltrexone combination or test drug 
administered in an assay of thermal nociception at 50°C and 54°C in rhesus monkeys. 
 %MPE
max 
50°
C 
54°
C 
Drug or Drug 
Mixture 
M1414 M1473 M1478 M150
3 
M1414 M1473 M1478 M1503 
Fentanyl 100 100 100 100 87 100 100 100 
1:0.025 
Fentanyl/Naltrexone 
100 100 100 100 81.1 100 100 100 
1:0.074 
Fentanyl/Naltrexone 
84.2 100 100 3.3 37.6 62.7 62.2 4.7 
1:0.22 
Fentanyl/Naltrexone 
9 6.6 42.2 10.4 18.1 10 44.2 1.1 
(−)-Naltrexone 9.5 2.1 -12.6 -1.6 3.2 1.8 -0.3 0.6 
(±)-Methadone 100 100 100 100 100 100 100 100 
(−)-Oxycodone 100 100 100 100 71.4 100 86.1 100 
(−)-Morphine 100 100 100 100 74.9 52.8 54.7 100 
(−)-Nalbuphine 100 100 100 100 52.8 100 71.9 31.7 
(±)-Buprenorphine 73.2 100 100 100 32.1 18.7 29.3 16.5 
NAQ 4.6 5.9 28.8 8 6.4 1.1 16.1 2.8 
 
Table 3: Fentanyl ED50 values and (95% confidence limits) administered alone or following 
a 15-min pretreatment with naltrexone (0.0032-0.032 mg/kg), 10 mg/kg NAQ, or 0.032 
mg/kg fentanyl/naltrexone (1:0.22) mixture in an assay of thermal nociception at 50°C and 
54°C. Data are presented as the mean of 3 monkeys for the naltrexone pretreatment studies 
and mean of 4 monkeys for the NAQ and fentanyl/naltrexone mixture pretreatment studies. ‡ 
denotes non-overlapping 95% confidence limits (CL). 
 ED50 in mg/kg (95% CL) 
 50°C 54°
C 
Fentanyl alone 0.006 (0.006, 
0.006) 
0.018 (0.018, 0.018) 
+ 0.0032 mg/kg Naltrexone 0.021 (0.016, 
0.028) ‡ 
0.035 (0.018, 0.069) 
+ 0.01 mg/kg Naltrexone 0.018 (0.013, 0.05) 
‡ 
0.169 (0.057, 0.228) ‡ 
+ 0.032 mg/kg Naltrexone 0.057 (0.043, 
0.128) ‡ 
0.257 (0.109, 0.608) ‡ 
Fentanyl alone 0.006 (0.005, 
0.006) 
0.014 (0.012, 0.017) 
+ 10 mg/kg NAQ pretreatment 0.041 (0.014, 
0.118) ‡ 
0.155 (0.122, 0.197) ‡ 
Fentanyl alone 0.006 (0.005, 
0.006) 
0.014 (0.012, 0.017) 
+ 0.032 mg/kg 
Fentanyl/Naltrexone 
 
(1:0.22) pretreatment 
 
< 0.017 (0.002, 
0.18) § 
 
0.035 (0.015, 0.08) 
 
§ ED50 value could only be determined in 2 out of 4 monkeys because no fentanyl dose 
produced < 50%MPE. 
Table 4: Estimated efficacy of each compound relative to the naltrexone-to-fentanyl 
continuum in proportion fentanyl units (95% confidence limits) for each of the eight 
MOR ligands tested in rhesus monkeys (n=4). Individual %MPEmax values were fitted 
to the nonlinear function generated from the group mean results shown in Figure 4A. 
Test Drug Proportion Fentanyl (95% 
CL) 
  
Fentanyl 0.94 (0.77, 1.12) ¶, #, ∏ 
(±)-Methadone 1 (1, 1) ¶, #, ∏ 
(−)-Oxycodone 0.86 (0.58, 1.13) 
(−)-Morphine 0.71 (0.4, 1.02) 
(−)-Nalbuphine 0.7 (0.37, 1.03) 
(±)-Buprenorphine 0.51 (0.47, 0.54) # 
NAQ 0.26 (0.16, 0.36) 
(−)-Naltrexone 0.12 (-0.1, 0.33) 
¶ Significantly different from Naltrexone (p < 0.05) 
# Significantly different from NAQ (p < 0.05) 
∏ Significantly different from Buprenorphine (p < 0.05) 
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Chapter 5: Discussion 
 
This dissertation examined MOR agonist interactions on preclinical endpoints related to 
pain in nonhuman primates. There were three main findings. First, NMDA receptor antagonists 
failed to enhance the antiallodynic effects of either a moderate (nalbuphine) or high (oxycodone) 
efficacy MOR agonist. Second, the NOP receptor agonist Ro 64-6198 potentiated the 
antinociceptive effects of MOR agonists regardless of efficacy; however, the effect was far more 
modest than previously reported and was only observed under a narrow range of experimental 
conditions. Third, fixed-proportion MOR antagonist (i.e. naltrexone) and agonist (i.e. fentanyl) 
mixtures were successful in decreasing antinociceptive efficacy in an antagonist proportion-
dependent manner. Overall, the results described in this dissertation add to the growing body of 
literature examining candidate opioid adjuncts to produce opioid-sparing effects by identifying 
pharmacological and experimental limitations of previously examined opioid interactions and in 
strengthening the case for employing complementary behavioral measures in opioid combination 
experiments. Furthermore, this dissertation provided several experimental design insights to 
guide future preclinical pain and candidate analgesic drug development research. 
 
1. NMDA antagonist and opioid agonist interactions 
The main finding of Chapter 2 was that the NMDA receptor antagonists ketamine and 
MK-801 failed to enhance the antiallodynic effects of either the moderate (i.e. nalbuphine) or 
high (i.e. oxycodone) efficacy MOR agonists. Furthermore, NMDA antagonist and MOR agonist 
combinations reduced the experimental therapeutic index of the MOR agonists to selectively 
produce antiallodynia vs. behavioral sedation as compared to the MOR agonists alone. 
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Generally, the experimental therapeutic index decreased as the amount of NMDA receptor 
antagonist in the mixture increased. This would suggest that increasing NMDA antagonist doses 
in fixed proportion combinations with MOR agonists would be more detrimental than producing 
clinically beneficial effects. These results further highlight (1) the utility of nonhuman primates 
in preclinical assessments of candidate analgesics and (2) the necessity of employing 
complementary assays to discern the selectivity of antinociceptive vs. sedative effects of putative 
MOR agonist combination medication therapies for clinical pain management. 
The reported antinociceptive interactions between the NMDA receptor antagonists and 
MOR agonists were consistent with previous reports in rhesus monkeys (Banks et al, 2010) and 
humans (Lee and Lee, 2016). However, these results are inconsistent with a previous study in 
squirrel monkeys (Allen and Dykstra, 2001). The lack of a synergistic interaction in Chapter 2 
results and those reported in Banks (2010) are in contrast to results reported by Allen and 
Dykstra (2001). These differences are most likely attributed to the noxious stimulus utilized in 
each experimental design. For example, a thermal noxious stimulus was utilized in both Chapter 
2 and Banks (2010) whereas Allen and Dykstra (2001) utilized a mild electrical shock as the 
noxious stimulus. Interactions between NMDA receptor antagonists and MOR agonists have 
been previously shown to differentially affect antinociceptive responses depending upon 
stimulus modality. For example, in clinical laboratory experiments the NMDA receptor 
antagonist ketamine potentiated the antinociceptive effects of fentanyl against an electrical, but 
not thermal noxious stimulus (Tucker et al, 2005). Thus, stimulus modality appears to be a 
critical factor in the antinociceptive interactions between NMDA receptor antagonists and MOR 
agonists. These discrepancies may suggest further limitation to any potential clinical utility that 
NMDA antagonists and MOR agonists may have in the management of pain. 
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The reported antinociceptive interactions between NMDA receptor antagonists and MOR 
agonists in Chapter 2 were also inconsistent with several previous rodent studies examining 
MOR agonist and NMDA antagonist interactions (Baker, Hoffman, Meert, 2002; Holtman Jr et 
al, 2008). For example, dextromethorphan, ketamine, and ketamine metabolites (S(+)- and R(-)-
norketamine) were previously shown to enhance the antinociceptive effects of MOR, but not 
KOR and DOR, agonists in rats across multiple pain states (Baker, Hoffman, Meert, 2002; 
Holtman Jr et al, 2008). Since the noxious stimuli didn’t differ between Chapter 2 and the 
aforementioned rodent studies (e.g. warm-water tail withdrawal vs. hot plate, respectively), this 
apparent discrepancy suggests differences between rodents and nonhuman primates in 
antinociceptive effects mediated by NMDA receptor activity (i.e. neuroanatomical differences). 
Moreover, one of the major differences between the rodent studies and the experiments in Aim 1 
is several of the NMDA receptor antagonists utilized (eg. dextromethorphan, S(+)- and (R-)-
norketamine). A meta-analysis suggested that ketamine combinations with opioids for 
management of acute pain were not superior to the opioid alone and may exacerbate some 
undesirable side effects (Lee and Lee, 2016). Thus, the clinical utility of ketamine or other 
NMDA antagonists as an adjunct to MOR agonists for the management of pain is very unlikely. 
Moreover, ketamine-MOR combinations in several clinical trials lead to increased 
“neuropsychiatric” side effects in some patients (Lee and Lee, 2016). Overall, the results 
reported in this dissertation were consistent with conclusions from this meta-analysis and support 
the utilization of nonhuman primates and multi-modal preclinical dependent measures to develop 
candidate analgesics. 
 
2. NOP agonist and opioid agonist interactions 
	
 
 
 
122	
The main finding of Chapter 3 was that the high efficacy NOP receptor agonist Ro 64-
6198 (Jenck et al, 2000) potentiated the antinociceptive effects of MOR agonists regardless of 
efficacy; however, this effect was far more modest than previous reports, and was only observed 
to occur under a narrow range of experimental conditions. Furthermore, the previously reported 
antinociceptive effects of Ro 64-6198 alone in rhesus monkeys (Ko et al, 2009; Podlesnik et al, 
2011; Cremeans et al, 2012) were not replicated at comparable or 3-fold higher doses (0.1 and 
0.32 mg/kg IM, respectively).  
The results indicating that NOP agonists did not impact our complementary undesirable 
MOR agonist effect add to the existing reports of buprenorphine and NOP agonist combinations 
and bivalent MOR-NOP agonists. Ro 64-6198 had been previously shown not to increase the 
potency or efficacy for buprenorphine to produce respiratory depression or pruritis (Cremeans et 
al, 2012). Furthermore, the mixed-action MOR-NOP agonist BU08028 showed no significant 
production of respiratory depression (compared to MOR agonist alone), and did not maintain 
drug-self-administration (Cremeans et al, 2012; Ding et al, 2016). While some of these 
undesirable effects may still persist at higher doses of buprenorphine+Ro 64-6198 combinations 
(i.e. abuse liability and respiratory depression), the increase in antinociceptive potency compared 
to buprenorphine alone may result in a decrease in the occurrence of these opioid-related adverse 
effects (Li, 2019). Overall, these data would support the utility of MOR+NOP combinations for 
clinical pain treatment. 
One potential limitation of the clinical utility of NOP+MOR combinations is the lack of 
pharmacological selectivity as NOP activity may potentiate the undesirable effects of MOR 
agonists as well. The potentiation of both the antinociceptive effects and antagonism of rate-
decreasing effects of nalfurafine by Ro 64-6198 at a single dose (0.01 and 0.001 mg/kg, 
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respectively) further complicate the translatability of NOP+MOR agonist combinations to 
clinical utility. These findings suggest that Ro 64-6198 potentiation is perhaps not selective for 
(1) mu-opioid receptor agonists and (2) opioid receptor-mediated antinociception. If this 
potentiation is not selective for MOR agonists, this could suggest another false-positive result as 
DOR and KOR agonists will produce antinociception in preclinical assays, but are not clinically 
useful analgesics. However, this could also suggest that mixed action MOR/KOR agonists (such 
as butorphanol) may be viable candidates for future NOP combinations.  
 
3. Opioid adjuncts as a useful approach to produce an opioid-sparing effect 
In comparison with interactions between MOR agonists and other candidate adjuncts 
targeting other receptors, the MOR agonist antinociceptive potentiation reported in this 
dissertation is much more modest (NOP-MOR) or nonexistent (NMDA-MOR). For a list of 
previous Mu-Plus interactions, see Table 1. For example, the serotonin uptake inhibitors 
fluoxetine and clomipramine potentiated the antinociceptive effects of MOR agonists in rats and 
rhesus monkeys, respectively, by nearly 10-fold (Nayebi et al, 2001; Banks et al, 2010). 
Furthermore, the cannabinoid receptor agonists CP 55,940 and Δ9-THC both potentiated the 
antinociceptive effects of MOR agonists nearly 10-fold in both rhesus monkeys and rats 
(Maguire and France, 2014, 2018). Moreover, in some cases, DOR potentiation of MOR 
mediated antinociception was greater than reported in Chapters 2 and 3 experiments (e.g. SNC80 
+ methadone, fentanyl, or nalbuphine), but was roughly similar with other DOR-MOR 
combinations (e.g. SNC80 + morphine and MSF61 + fentanyl) (Stevenson et al, 2003; Negus et 
al, 2009). Additionally, the KOR agonist nalfurafine potentiated oxycodone antinociception in 
rodents to a greater degree, roughly 10-fold, than results reported in the Aim 1 and 2 experiments 
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(Townsend et al, 2017), and mixtures with the KOR agonist spiradoline and morphine or 
etorphine potentiated antinociceptive effects of the MOR agonist alone by roughly 10-fold and 5-
fold, respectively (Minervini et al, 2018). Overall, the absence of NMDA antagonist 
enhancement of MOR agonist antinociception and the small magnitude of NOP agonist 
enhancement of MOR agonist antinociception compared to published literature with other 
potential adjuncts targeting other receptor systems do not support the further development of 
either NMDA antagonists as MOR agonist adjuncts but does support NOP agonists as candidate 
analgesics for the treatment of acute pain. However, it is unknown if NOP-MOR agonist 
combinations or bivalent ligands will be superior to MOR agonists alone in the production of 
analgesia. Finally, the results do provide insight into the applicability of opioid-combination 
experiments for considerations into the experimental designs of future MOR agonist combination 
medication development experiments. 
Despite promising results from previous proposed adjunct combinations (eg. serotonin 
uptake inhibitors, cannabinoid receptor agonists, DOR agonists, KOR agonists, NOP agonists, 
imidazoline I2 receptor agonists) there does not seem to be much translational progress from 
preclinical results to clinical application of multiple molecule therapies. The increasing number 
of recent clinical trials suggests there seems to be more interest in one alternative to fixed-
proportion drug mixtures: bivalent ligands that target multiple receptor systems of interest. For 
example, the NOP-MOR bivalent ligand cebranopadol has been investigated in a wide range of 
clinical trials to varying successes. However, each of these approaches has their pros and cons. 
For example, combination medication therapies have the advantage of (typically) being readily 
available, FDA-approved medications that healthcare professionals can prescribe to patients. 
Moreover, this approach may allow for the “fine-tuning” of the proportions of each drug in the 
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mixture towards an effort of maximizing desirable effects and minimizing undesirable effects. 
However, fixed-proportion combination opioid medications require overlapping pharmacokinetic 
characteristics of each drug, such as onset and duration of action. On the other hand, bivalent 
ligands have the capacity to bypass the requirement for pharmacokinetic concordance, as a single 
molecule will activate both receptors of interest. However, these bivalent compounds would 
require a longer time to develop and move through the drug development stages to ensure safety 
and efficacy compared to existing and approved medications. Moreover, this approach may only 
be viable for certain receptor systems with similar enough binding pockets to allow an overlap in 
the molecule’s pharmacophore composition such that the molecule could appreciably activate 
both receptors. It seems likely that the best choices between these two approaches would be on a 
case-by-case basis, but experiments directly comparing the two could greatly elucidate the 
situations under which each approach would be the most beneficial 
 
4. Fixed-proportion opioid agonist and antagonist interactions 
The main finding of Chapter 4 was that fixed-proportion mixtures of a competitive 
agonist and antagonist at a common receptor produced antagonist proportion-dependent 
decreases in efficacy. These results showed the usefulness of agonist-antagonist fixed-proportion 
combinations to predict a “window of effect” detectable by various assays. In this case, the 
windows of effect of MOR agonists for warm water tail withdrawal at both 50 and 54 °C in 
nonhuman primates was determined. This could allow for researchers to probe a wide variety of 
different assays and compare the efficacy requirements for agonists active at various receptor 
systems to produce an effect in a given assay. Recently, this approach has been shown to be 
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reproducible with rats in both a tail-withdrawal and drug-discrimination procedure utilizing 
MOR agonists (Schwienteck, 2019).  
Efficacy is defined as a ligand’s ability to activate a receptor to generate a response in a 
biological system and has long been known to be a major determinant in drug effects both in 
vivo and in vitro (Blumenthal and Garrison, 2011). One of the major themes of this dissertation 
was determining the role of MOR efficacy in production of behavioral effects (e.g. 
antinociception and decreases in operant rates of responding) alone and in combination with 
other compounds (i.e. NMDA antagonists, NOP agonists, and naltrexone). This work further 
expanded upon the concept of efficacy requirements for the detection of a biological effect in in 
vivo behavioral assays such that moderate efficacy MOR agonists (e.g. buprenorphine) are 
incapable of producing (1) meaningful antinociception at higher intensity noxious stimuli (ie. 
54°C) and (2) significant decreases in operant rates of responding, both of which high efficacy 
agonists (e.g. fentanyl) are capable of producing.  
These reported results support previous suggestions that efficacy requirements to produce 
antinociception and other effects can be ranked, and the current data would propose the efficacy-
effect ranking of these procedures as 50°C antinociception < schedule-controlled responding < 
54°C antinociception (Walker et al, 1993; Banks et al, 2010; Maguire and France, 2014). These 
findings suggest interesting implications for both preclinical research and clinical practice as 
they propose the potential for behavioral assays to be ranked based upon their sensitivity for 
detection of biological effects along a specific range of drug efficacies. If the receptor system has 
been adequately probed, efficacy-effect procedures could be a useful tool to inform researchers 
of the proper assay to employ when investigating a relatively novel compound to ensure 
detection of any potential biological effects. One limiting factor, however, is that it is unknown if 
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these results would be supported with drugs active at a system other than the MOR. One would 
hypothesize that the results are translatable due to the generalizability of the properties of 
“efficacy” across a range of drug classes. Clinically speaking, these efficacy-dependent effects 
support the idea that low efficacy MOR agonists are effective in reduction of more moderate 
pain states with a lower incidence of undesirable side effects (Davis, 2012), while higher efficacy 
MOR agonists would be more effective in treatment of more severe pain states. Clinically, this 
could provide a tool for physicians to tailor drug effects to the need of the patient. For example, 
this approach could be used to combine fentanyl and naltrexone at a precise fixed-proportion to 
mitigate a patient’s moderate pain symptoms without the potential for producing respiratory 
depressant effects, such as with buprenorphine, but permitting a higher degree of antinociceptive 
efficacy.  
 
5. In vivo investigation of NAQ in rhesus monkeys 
This work was the first evaluation of the in vivo efficacy of the novel MOR ligand, 17-
cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3-carboxamido)morphinan 
(NAQ) in monkeys. NAQ was shown to be ineffective in producing any suppression of operant 
rates of responding in the assay of schedule-controlled responding and was shown to be 
ineffective in producing antinociception in the tail withdrawal assay. These effects were 
consistent up to doses which both (1) antagonized the antinociceptive effects of fentanyl in the 
tail-withdrawal procedure, and (2) were maximally allowed due to solubility constraints. These 
results were generally consistent with those in rats, but subtle species differences did emerge. 
One study reported no significant decreases in rates of responding in a drug discrimination 
procedure or significant antinociception in a tail-flick procedure (Schwienteck et al, 2019), and 
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another reported no significant antiallodynia but a significant decrease in rates of food-
maintained responding (Siemian et al, 2016). The antagonistic effects of NAQ were also 
generally consistent with previously reported effects in both mice and rats (Yuan et al, 2015; 
Siemian et al, 2016; Schwienteck et al, 2019). Overall these results demonstrate a concordance in 
NAQ activation of the MOR receptor at the organismal level from rodents to nonhuman primates 
and further support the utility of NAQ as a low efficacy MOR ligand. 
Although the modeling resulted in NAQ being quantified as 0.25 proportions of fentanyl, 
this was still shown to be insufficient to detect any behavioral effect in either of our assays. This 
suggests that in either schedule-controlled responding or warm-water tail withdrawal, that 
ligands producing ≤ ~25% of fentanyl’s receptor activation will fail to produce a detectable 
effect suggesting that these procedures are only useful in probing higher efficacy MOR 
compounds (≥ ~50% of fentanyl receptor activation). In light of this the need to both (1) develop 
new and (2) identify existing behavioral assays which will allow for the detection of effects 
along the lower 50% of the fentanyl proportion efficacy range is an imperative goal. One such 
potential assay to detect effects of lower efficacy MOR agonists could be intracranial self-
stimulation. For example, NAQ has been shown to produce detectable behavioral effects 
including rate-decreasing effects in this procedure in opioid-naïve rats and weak facilitation in 
opioid-exposed rats (Altarifi et al, 2015; Moerke & Negus, 2019). Moreover, drug discrimination 
procedures may also provide an avenue for detection of behavioral effects mediated by lower 
efficacy MOR ligands as NAQ was reported to occasion fentanyl-appropriate responding in rats 
trained to discriminate fentanyl (Schwienteck et al, 2019). Overall, the literature supports the 
utility of NAQ as a low efficacy MOR ligand in preclinical pharmacological research. 
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6. Experimental design considerations for future preclinical pain research 
Tail-Withdrawal Procedure 
 The warm-water tail withdrawal procedure has been historically used in the field of 
behavioral pharmacology to evaluate the antinociceptive effects of novel compounds, including 
novel MOR agonists. However, the warm-water tail withdrawal procedure is not without 
limitations and the predictive validity of non-opioid candidate analgesics in the warm-water tail 
withdrawal procedure has not been great. One limitation is that the procedure relies entirely upon 
a reflexive behavior that produces solely a transient nociceptive response that can be “escaped” 
by removal of the tail from the noxious stimulus (e.g. heated thermos) (Negus, 2019). Because 
the tail withdrawal behavior relies on a reflex arc within one area of the spinal cord (Weng and 
Schouenborg, 1996), the receptors mediating any antinociceptive effect may be (1) fewer in 
number than those responsible for more complex pain states and (2) limited to sub-cortical areas 
which are crucial in the emotional aspect of pain perception (Negus, 2019). In support of this 
hypothesis, activation of peripheral opioid receptors is sufficient to produce antiallodynia in tail-
withdrawal procedures (Ko et al, 1998, 1999, 2002), however neither peripheral nor centrally 
activating KOR ligands are currently clinically utilized analgesics. This result suggests a major 
limitation in the tail-withdrawal procedure if our intention is to translate results to a clinical 
situation. 
The tail-withdrawal procedure does appear to model aspects of acute pain; for example, 
some of the most robustly effective compounds to produce antinociception in this procedure are 
MOR agonists and MOR agonists are still the most commonly utilized clinical interventions for 
moderate to severe acute pain (e.g. post-operative pain states) (Whiteside et al, 2008). However, 
the translatability of the tail withdrawal procedure to human pain states is highly problematic for 
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three major reasons: (1) the high potential for false-positives, (2) the issue of dose-requirements 
to detect some effects, and (3) the inability to detect effects for clinically utilized analgesics (e.g. 
NSAIDs). 
Because the tail withdrawal procedure is a pain-stimulated endpoint (meaning that the 
measured response increases in duration, intensity, or frequency in the presence of the noxious 
stimulus), it is highly susceptible to false-positives from compounds that produce motor 
impairment (Negus, 2019). If a drug is capable of decreasing behavior, then the drug should 
decrease the tail withdrawal response (indicative of antinociception in this procedure) at some 
dose. This phenomenon is well characterized; for example, MK-801, PCP, THC, loperamide, and 
nalfurafine have all been reported to produce decreases in tail withdrawal behaviors in this 
procedure despite none of these compounds being clinically prescribed analgesics (France et al, 
1989; Endoh et al, 2001; Butelman et al, 2004; Maguire and France, 2014). Furthermore, the 
conflicting reports on the antinociceptive effects of Ro 64-6198 in this procedure obscure the 
determination of whether a candidate analgesic is a clinically effective analgesic compound (i.e. 
a compound sufficiently capable of reducing nociceptive signaling rather than simply producing 
a motor-depressant-related reduction in pain responding) or an example of a false-positive (Ko et 
al, 2009; Cornelissen et al, 2019). 
The second major limitation precluding this procedure from being a strong predictive 
translation model is the major discrepancies in dose-requirement for detection of an effect. The 
doses typically required to produce an antinociceptive response in assays utilizing endpoints such 
as tail-withdrawal tend to be nearly an order of magnitude greater than typically required for 
more post-operative cases in humans (Whiteside et al, 2008). For example, the dose of 
methadone (3.2 mg/kg) required in these experiments to produce 100%MPE at 54°C also 
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produced maximal behavioral suppression in the assay of schedule-controlled responding, and 
occasionally required antagonist-reversal. This suggests that the efficacy requirements for 
antinociceptive effects are much greater in a preclinical tail withdrawal procedure than those 
required for analgesic effects in clinical settings. One negative consequence of these 
discrepancies could be that the dose-ratios of opioid combinations chosen for preclinical 
experiments (especially if based upon antinociceptive ED50’s) could be massively greater than 
those clinically relevant. This could result in determining drug and dose relationships that are 
entirely irrelevant for translatability and may be entirely different than the relationships between 
those drugs at clinically relevant dose-ratios. Therefore, not only is this procedure capable of 
producing false-positives, but potentially also false-negatives. 
Finally, this procedure is also severely limited in its ability to produce highly translatable 
results due to the challenging nature of chronic dosing in such experiments. Pain remains a 
chronic condition in a number of patients requiring novel and improved treatments. Clinically 
relevant experimental designs might necessitate more chronic administration to include variables 
such as antinociceptive tolerance and metabolic alterations, which are likely to greatly impact the 
progression and treatment of pain in humans (Whiteside et al, 2008).  
 
Schedule-Controlled Responding  
 Schedule-controlled responding provides one complementary dependent measure to 
determine behavioral selectivity when using a pain-stimulated behavior such as the warm-water 
tail withdrawal procedure to study antinociception. In addition, the schedule-controlled 
responding procedure allowed for the calculation of an experimental “therapeutic index” as one 
measure of the range of the –fold doses at which a drug can be administered without recruiting a 
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specific undesirable effect. For example, aim 1 determined the experimental therapeutic index 
for oxycodone to be five, meaning that oxycodone was five times more potent to produce 
antiallodynia than sedation. This index does provide some clinical utility and translatability as 
one of the major goals for pain management is to adequately mitigate pain symptoms and restore 
daily life function and improve quality of life metrics (Wells et al, 2008). Although this measure 
is useful to identify selectivity in antinociceptive effects and may have some clinical relevance, it 
is maybe potentially more fruitful to employ a multi-modal assessment of a number of 
undesirable side effects in future experiments. 
 Arguably, the most detrimental undesirable MOR agonist effects of greatest concern are 
lethality and abuse; these endpoints would be best measured via investigation of respiratory 
depression and reinforcing effects. In support of these MOR agonist effects being of the greatest 
concern, and therefore the most important to monitor in any potential opioid-combination 
experiments, is the Volkow and Collins (2017) report on addressing the opioid crisis which 
outlined the need for novel opioid reversal interventions, opioid use disorder treatments, and 
non-addictive treatments for pain. In light of this, there may be side effects of greater 
significance to investigate in opioid-combination experiments (in an attempt to potentially 
mitigate) as compared to sedation. This will be further elaborated upon in the proposed 
alternatives section. 
Proposed Alternatives  
1) Future preclinical pain research should utilize complementary pain-stimulated and 
pain-depressed behaviors to assess therapeutic effects of novel analgesics and analgesic adjuncts. 
Employing both pain-stimulated and pain-depressed behavioral assays would likely mitigate the 
probability of false-positive analgesic compounds. Moreover, the clinical experience of pain 
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would be more closely modeled by pain-depressed behaviors, thus would likely serve as a strong 
predictor of clinical outcomes.  
2) Future preclinical pain research should also utilize complementary behaviors to assess 
undesirable effects. For example, two prominent undesirable effects of MOR agonists are 
respiratory depression and abuse liability, in addition to behavioral depression/sedation. This is 
an imperative measure to employ in future research because of the danger that these effects can 
have on both the user and the society, thus it is important to monitor that adjuncts are not 
exacerbating the abuse potential or lethality of the opioids they are being combined with.  
3) Given the additional ethical considerations involving the use of nonhuman primates in 
preclinical pain research, the utility of nonhuman primates as research subjects in future 
preclinical pain research will be limited. Thus, future experiments should aim to utilize rodent 
models and strive to develop novel paradigms to best improve translatability. 
However, if the preclinical approach to opioid combination medication is to continue 
being utilized, even in a solely informative capacity, it is imperative for this body of data to 
further inform improvements that can be made. Firstly, there needs to be a paradigm shift in the 
field moving from the antiquated reliance upon pain-stimulated behaviors to probe 
antinociceptive effects to employments of pain-depressed behaviors. These behaviors are much 
more similar to the human clinical condition of pain and are hypothesized to have higher 
predictive validity of analgesic effectiveness in humans (Negus, 2019). Secondly, 
complementary measures of undesirable effects should be more focused on investigating the 
clinically concerning MOR side effects such as respiratory depression and abuse liability. Thus, 
opioid-combination experiments should be more likely to include these secondary measures 
probed with assays such as plethysmography, self-administration, or drug-discrimination to 
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determine the potential of candidate receptor systems to mitigate lethality and abuse cause by 
MOR agonists. Finally, preclinical experiments should be designed to more closely resemble a 
human pain condition in which the patient’s treatment is impacted by factors such as 
antinociceptive tolerance and metabolic factors. This would be accomplished with more long-
term studies with increased daily dosing frequency to more accurately model the regimen of 
patients receiving pain medication. Moreover, a less transient and “escapable” pain stimulus 
would more likely reflect the progression of the patient’s state as these factors are very likely to 
impact the ability of the analgesic to effectively relieve pain. 
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